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Abstract 
 
 
Embryonic stem cells (ESCs) are pluripotent due to their ability to differentiate 
into any cell type of the body, including functional gametes. These cells are also 
capable of infinite self-renewal and are highly receptive to genetic modification. 
The use of ESCs as a reproductive tool offers an exciting platform for farmers to 
efficiently amplify or introduce desirable agricultural traits within their herd. 
Unfortunately, all attempts to derive naive pluripotent ESCs from livestock 
animals have been unsuccessful. This is most likely attributed to a poor 
understanding of pluripotency specification in these animals. Nanog and Mbd3 
are two proteins which are intimately involved in early embryonic development 
and pluripotency in the mouse. However, their specific function in livestock 
animals remains unknown. The primary aim of this research project was to 
determine the feasibility of using a microRNA-mediated silencing approach to 
knockdown these two proteins in a bovine model.  
 
Three candidate microRNAs, designed for each gene transcript, were cloned into 
the BLOCK-iTTM pcDNATM6.2-GW/EmGFP-miR expression plasmid. Before 
application in an in vivo system, each microRNA was transiently screened in vitro 
to determine its specificity and knockdown potential. For screening purposes, 
various attempts were made to generate a stable bovine NANOG expression 
fibroblast line using an inducible piggyBac transposon expression system. 
However, stable integration rates were lower than expected and all surviving and 
overexpressing cell clones eventually entered into a non-proliferate state of 
cellular senescence. The knockdown potential of the NANOG microRNAs was 
eventually determined by transient cotransfection with a constitutively active 
NANOG expression plasmid into a bovine embryonic fibroblast line. All three 
NANOG-specific microRNAs were able to efficiently knockdown NANOG 
protein expression. The highest knockdown efficiency was 89% as quantified by 
immunocytochemistry.  By contrast, a MBD3 knockdown effect was not visible 
after transient expression of the MBD3-specific microRNAs, likely due to the 
longevity of the MBD3 protein which has a half-life of around 48 hours.  
Abstract 
 
iv 
 
The practicality of the BLOCK-iTTM microRNA expression system for functional 
gene analysis relies on its ability to generate stable knockdown cell lines which 
could then be used as donor cells for somatic cell nuclear transfer cloning and 
production of bovine knockdown embryos. Despite the slow proliferative nature 
of the stable transfectants and their frequent failure to expand during selection, we 
have been able to eventually generate GFP-microRNA expressing stable 
knockdown cell clones, suggesting that this system is still a feasible option for 
investigating the biological functions of NANOG and MBD3 in cattle.   
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Introduction 
 
 
By 2050, the human population is expected to exceed 9 billion (FAO, 2009). To 
feed such a population will require a 50% increase in food production from what 
is currently being achieved (FAO, 2009). In addition to meeting these demands, 
farmers will also have to deal with an increasing social pressure on environmental 
sustainability as well as resource limitations as expanding metropolitan areas 
begin to envelop surrounding pastoral land. Improving animal productivity is thus 
an important and immediate objective for the pastoral industry, as well as a 
pressing priority for governments around the world.  
 
For centuries, farmers have been selectively breeding animals based on high 
productivity characteristics (Phillips, 2010). However, owing to the long gestation 
time of ruminants (150 – 280 days) and a prior lack of genetic understanding, 
productivity selection based on phenotypic observations was painstakingly slow 
and often unreliable (Hernandes Gifford & Gifford, 2013). In the last few decades, 
a number of molecular reproductive technologies such as artificial insemination 
(AI), in vitro production of embryos (IVP) and somatic cell nuclear transfer 
(SCNT) cloning have radically improved the speed of trait selection and 
revolutionised animal breeding strategies. 
  
Whilst research has been directed into improving upon these existing molecular 
reproductive technologies, alternative avenues for accelerated breeding are also 
currently being explored. The generation of embryonic stem cells (ESCs) from 
mice in 1981 was a ground-breaking discovery in the scientific and medical field 
(Martin, 1981, Evans & Kaufman, 1981). In the decades that have followed, there 
has been immense interest and effort in deriving analogous cells from other 
mammalian species. The concept of using livestock-derived ESCs as a 
reproductive tool for accelerated breeding is now beginning to gather support 
within the agricultural community and may just be the next ‘big thing’ in 
reproductive technologies. 
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ESCs are considered the unicellular equivalent to a whole animal and are derived 
from early preimplantation embryos (Oback & Huang, 2014). These cells have 
two important hallmarks; firstly, they have the ability to self-renew indefinitely 
without karyotypic change allowing them to continually proliferate in culture, and 
secondly, they are capable of differentiating into any cell type found in the adult 
animal including functional gametes – a phenomenon known as pluripotency 
(Blair et al., 2011). These cells are also highly receptive to homologous 
recombination (HR), enabling precise genetic modification of the genome 
(Capecchi, 2005). Because of these properties, ESCs have radically transformed 
our understanding of mammalian gene function and are considered molecularly 
and functionally one of the best-defined cell types (Oback & Huang, 2014). 
 
From an animal breeding perspective, ESCs have the ability to shift the initial 
stages of reproduction from the field to the laboratory and, in doing so, enable 
precise generation of genetically elite livestock animals. Currently, the 
conventional method of animal selection is based on genotyping the offspring 
after they are born (Oback & Huang, 2014). Under this system, there is no 
guarantee that the offspring will have inherited the desired traits of the parents. 
However, it is now becoming possible to apply genomic selection prior to birth, 
when the IVP embryo is only one week old (Fisher et al., 2012). At this stage, 
around 10 – 15 cells from the outer layer, the trophectoderm, can be removed and 
used for genome-wide single nucleotide polymorphism (SNP) analysis. Because 
the embryo is particularly amenable to alterations in cell number, it is not 
destroyed in the process (Tarkowski & Wroblewska, 1967).   
 
After confirmation that the embryo is of high genetic merit, the farmer may decide 
to transfer the embryo into a receptive female, and in 40% of cases, that embryo 
will develop to term (Wells et al., 2003). Alternatively the farmer could instead 
choose to amplify the desirable genotype of that embryo by extracting its 
pluripotent cell population and generate an ESC line. The stem cell line could then 
serve as a reservoir for high quality genetics and, under certain conditions, a select 
portion of those ESCs could be molecularly cued to differentiate into a variety of 
cell types, most importantly gametes (Fig. 1) (Murray et al., 2013). The 
generation of fully functional gametes from pluripotent stem cells is known as 
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cycling of gametes in vitro (COGIV) and a proof of principle study has already 
been achieved in mice (Hayashi et al., 2012). In essence, farmers would have the 
opportunity to produce as many high quality animals as required, replacing those 
within the herd of average productivity. 
 
Aside from the reproductive advantages ESCs offer, these cells are also highly 
efficient cellular vectors for genetic engineering, enabling genes of agricultural or 
medical value to be inserted into, or removed from the genome with much more 
precision and ease (Buecker et al., 2010). Combining ESC technology with 
transgenics would allow for the introduction of traits to improve not only 
productivity in livestock animals but also reproduction, animal health and feed 
conversion (Laible, 2009). From a biomedical perspective, livestock ESCs would 
be particular useful for biopharming applications. For example, using cattle as 
bioreactors for large scale production of biopharmaceutical proteins (Oback & 
Huang, 2014). Most importantly, the establishment of livestock ESC lines would 
help satisfy basic research interests enabling researchers to explore gene function 
and physiology in a larger mammalian model (Muñoz et al., 2008). 
 
 
Fig. 1. Potential reproductive applications of livestock ESCs. 
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ESCs have the potential to revolutionise the pastoral industry and change the way 
farmers generate high-value farm animals. However, despite extensive research 
efforts, attempts to derive bona-fide ESCs in any mammal other than rodents has 
been unsuccessful. This is particularly surprising given that the basic course of 
embryonic development is highly conserved throughout mammalian species 
(Wolpert & Tickle, 2011). Derivation in domestic animals, such as cattle, is not 
without fruition and has yielded cells which resemble ESCs both in their 
morphology and molecular profile (Evans et al., 1990, Mitalipova et al., 2001). 
These ESC-like cells have also been reported in a number of other domestic 
species, including pigs (Li et al., 2003), goats (Keefer et al., 1996), sheep 
(Notarianni et al., 1991), and horses (Saito et al., 2002). However, unlike 
authentic ESCs, ESC-like cells from livestock animals lack the capacity for 
continual propagation and become senescent after several passages (Talbot & 
Blomberg, 2008). Furthermore, ESC-like cells are yet to fulfil the stringent 
requirements which functionally define naïve pluripotency, them being teratoma 
formation, contribution to chimeric embryos, in particular the germline, and 
tetraploid complementation (Oback & Huang, 2014).  
 
Attempts to derive livestock ESCs have so far relied on what is known about 
embryonic development and pluripotency maintenance in mice. However, there 
are a number of important differences between mice and livestock animals with 
regard to early embryonic development and the timing of key events (Oback & 
Huang, 2014). Furthermore, the molecular mechanisms responsible for cell 
lineage segregation have also been found to subtly differ between species 
(Kirchhof et al., 2000, Kuijk et al., 2008). This could imply that the specification 
of the pluripotent cell population of the embryo is not evolutionary conserved and 
may explain why ESCs have failed to be captured in other animals. It seems that 
the mouse can no longer be used as a reliable model for ESC derivation in other 
mammals. Instead, it is imperative that more species-specific research is carried 
out to develop a better understanding of pluripotency regulation, specifically in 
livestock animals. This knowledge will likely assist in refining ESC derivation 
protocols and cell culture conditions which will hopefully eventuate in the 
establishment of authentic livestock ESC lines. 
 
Introduction 
 
5 
 
The aim of this this research project was to examine the function of two proteins, 
NANOG and MBD3, that have been implicated as playing vital roles in murine 
(mouse) embryonic development and pluripotency. Using cattle (Bos taurus) as a 
model organism, this research will provide the necessary cross-species 
comparison to validate whether these two proteins are also important for 
pluripotency regulation in livestock animals.  
 
To appreciate the biological role of NANOG and MBD3, a brief overview of 
mammalian preimplantation development will firstly be provided in the literature 
review of this thesis followed by an explanation of how ESC are derived and 
maintained in vitro. The subsequent sections will then focus on what is already 
known about NANOG and MBD3 with regard to their biological functions in 
mice, highlighting any inconsistences or gaps within the literature that require 
further investigation. The technique of RNA interference will then be introduced 
including an explanation as to why it is the preferable method for functional gene 
analysis in livestock. The objectives of this research project will then be presented 
alongside an overview of the research strategy. 
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Chapter One: Literature Review 
 
 
1.1 Preimplantation Development 
In the mouse, fertilisation of an oocyte results in the formation of a single cell 
embryo, the zygote. Because the zygote has the capacity to give rise to the entire 
animal as well as all the supporting extraembryonic tissues it is said to possess 
totipotency (De Miguel et al., 2010). Approximately 36 hours after fertilisation, 
the zygote undergoes its first cleavage event where it divides in half to generate a 
2-cell embryo (Cockburn & Rossant, 2010). From there, the embryo continues to 
undergo a series of divisions as it works its way along the oviduct towards the 
uterus. By the 8-cell stage, the embryo begins to compact into a tight ball of cells, 
known as the morula. As the morula grows in cell number, the first wave of 
lineage segregation commences, signalling the end of totipotency (Takaoka & 
Hamada, 2012). As the outer and inner cells of the embryo segregate, a blastocoel 
cavity develops and two separate cell populations become apparent; the 
trophectoderm and the inner cell mass (ICM). An embryo at this stage is referred 
to as a blastocyst and consists of around 100 cells (Cockburn & Rossant, 2010). 
During the blastocyst stage, a second lineage segregation event takes place within 
the ICM resulting in the formation of an apical layer of cells, the hypoblast, which 
overlay a solid sphere of cells known as the epiblast (Fig. 2) (Rossant & Tam, 
2009). 
 
 
Fig. 2. Mammalian blastocyst after the second lineage segregation event. Three 
separate cell populations are apparent; the trophectoderm, hypoblast, and epiblast. 
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Of the three distinct cell populations now present within the blastocyst, only the 
epiblast will continue to develop the embryo. Although totipotency has been lost, 
the epiblast still possesses pluripotent cells. Following implantation, the epiblast 
will undergo gastrulation to generate the three embryonic germ layers (ectoderm, 
mesoderm, and endoderm) as well as the primordial germ cells (PGCs) (Oback & 
Huang, 2014). By contrast, the trophectoderm and hypoblast are not pluripotent 
and can only give rise to supporting extraembryonic tissues, such as the placenta 
and the yolk sac (Cockburn & Rossant, 2010). 
 
Compared to the mouse, bovine (cattle) embryonic development generally follows 
the same chronological order of events, albeit at a slower pace. Because the 
gestation time of mice is only 20 days, development has to occur very quickly and 
as soon as the blastocyst has hatched from its zona pellucida casing, the murine 
embryo immediately begins to implant into the uterine wall (Rossant & Tam, 
2009). By comparison, the cow which has a gestation time of 280 days, can have a 
much slower rate of embryonic development. Rather than implanting immediately 
after hatching, the bovine blastocyst instead elongates to form a long filamentous 
structure which allows it to efficiently exchange metabolites within the uterus 
(Blomberg et al., 2008). At the same time, gastrulation is also occurring – another 
important difference from the mouse development model. Only after the 
completion of gastrulation at around day 18-20 does the bovine embryo begin to 
attach, non-invasively, to the uterine wall (Vejlsted et al., 2006). This extended 
period of preimplantation development in cattle presents a significant challenge 
for ESC derivation and may offer an explanation as to why ESCs have not yet 
been captured in these animals. 
 
1.2 ESC Derivation and Maintenance 
Because of its pluripotent nature, the preimplantation epiblast tissue is the major 
derivation source for murine ESCs, although ESC lines have also been derived 
from morula stage embryos prior to lineage segregation (Eistetter, 1989, 
Strelchenko et al., 2004). To maintain murine ESCs in vitro, culture media is 
supplemented with the growth factors leukaemia inhibitory factor (LIF) and bone 
morphogenic protein (BMP4), which act via their respective signal transducers, 
STAT3 and SMAD proteins, to switch on a core set of pluripotency genes (Niwa 
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et al., 1998, Ying et al., 2003). Pluripotency promoting genes act to maintain the 
undifferentiated state by promoting self-renewal and inhibiting the expression of 
transcription factors which encourage differentiation (Boyer et al., 2005). In the 
mouse, three key transcription factors have emerged as being essential for early 
embryonic development and ESC identity and thus are considered the core 
regulators of the transcriptional pluripotency network (Nichols et al., 1998, Niwa 
et al., 2000, Mitsui et al., 2003, Chambers et al., 2003, Avillion et al., 2003, Masui 
et al., 2007, Kopp et al., 2008). They are Oct4, Sox2, and Nanog. 
 
Unlike Oct4 and Sox2, Nanog expression within the embryo is exclusively 
confined to the epiblast, making it an ideal diagnostic marker for naïve 
pluripotency (Silva et al., 2009). In the mouse, the ideal time for deriving naïve 
ESCs is between days 3.5 and 4.5 when the expression of Nanog is high 
(Czechanski et al., 2014). Upregulation of Nanog during this time has been found 
to result in the reactivation of the paternal X chromosome within female epiblast 
cells (Silva et al., 2009). This reactivation event is critical for obtaining ground-
state pluripotency and for allowing randomisation of the subsequent X 
chromosome inactivation event within the embryo proper (Silva et al., 2009). As 
such, high expression levels of Nanog, along with the presence of two active X 
chromosomes has become the most discriminatory marker for the naïve 
pluripotent state (Silva & Smith, 2008). 
 
The analogous time point for deriving naïve pluripotent stem cells from bovine 
embryos is still yet to be determined. Preliminary research has shown that 
NANOG expression is significantly upregulated between day 7 and day 8 of 
bovine embryonic development. Whereas expression of XIST, the non-coding 
RNA molecule responsible for silencing the X chromosome (Ng et al., 2007), is 
concomitantly downregulated (AgResearch, unpublished data). These initial 
findings suggest that the transient naïve pluripotent cell population, capable of 
giving rise to authentic ESCs, may be present within the day 8 bovine blastocyst. 
However, a greater appreciation of NANOG’s role in bovine embryonic 
development is still required. Results from such research will determine whether 
NANOG can also be used as a diagnostic marker for naïve pluripotency in 
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livestock which will likely assist in the ultimate goal of establishing authentic 
ESC lines for these animals. 
 
1.3 The Naïve Pluripotency Marker, Nanog 
Nanog is a unique homeodomain containing protein that was initially discovered 
during a polymerase chain reaction (PCR) screen of a murine ESC 
complementary DNA (cDNA) library (Wang et al., 2003). Subsequently, two 
separate research groups also identified the same gene via different methods, and 
renamed it Nanog, after the mythical Celtic land of the ever young, Tir Na Nog 
(Mitsui et al., 2003, Chambers et al., 2003). Functionally, both groups were able 
to show that among the different factors tested, Nanog was the only factor capable 
of maintaining the pluripotency of murine ESCs in culture devoid of LIF. 
 
Structurally, Nanog is composed of three domains: an N-terminal domain, a 
homeodomain, and a C-terminal domain (Fig. 3) (Pan & Thomson, 2007). The C-
terminal domain, which contains a well-conserved ten pentapeptide tryptophan 
repeat series, possesses the highest level of transcriptional activity (Pan & Pei, 
2003, Oh et al., 2005). With regard to Nanog’s unique homeodomain, there is 
very low sequence identity between mammalian, avian, and teleost orthologs. 
However, all of the different Nanog orthologs were still capable of regulating 
mouse Nanog target genes (Theunissen et al., 2011). Upon further analysis, it was 
discovered that this conserved function was attributable to just two adjacent 
amino acids within the DNA recognition helix of the homeodomain, tyrosine (Y) 
42 and lysine (K) 43. 
 
 
 
 
Fig. 3. Schematic showing the domain structure of Nanog. ND, N-terminal domain. 
HD, homeodomain. CD1, C-terminal domain 1. WR, trypotophan repeat series. CD2, C-
terminal domain 2 (Adapted from Theunissen et al., 2011). 
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In mice, Nanog protein expression is first detected within the inner cells of the 
compacted morula and is restricted to the nucleus (Hatano et al., 2005). By the 
blastocyst stage, Nanog is exclusive to the ICM and is no longer detectable within 
the trophectoderm. As the blastocyst matures, Nanog expression becomes further 
confined to the epiblast and is subsequently absent from the hypoblast. 
Interestingly, numerous groups have reported a heterogeneous expression pattern 
of Nanog within epiblast cells, or their derived ESCs, with some cells having a 
higher expression level of Nanog than others (Singh et al., 2007, Toyooka et al., 
2008, Abranches et al., 2014). Initially, researchers suspected that the high 
expressing Nanog cells may represent a distinct population of pluripotent cells. 
However, further evidence revealed that the heterogeneous expression observed 
was both reversible and stochastic in nature (Abranches et al., 2014). Consistent 
with a role in pluripotency, Nanog is subsequently downregulated following 
implantation but remains detectable within the primordial germ cells (PGCs). 
Additionally, the abundance of Nanog within ESCs is also rapidly downregulated 
upon differentiation with no protein detectable within differentiated cells. 
 
1.3.1 Modulation of Nanog in Embryos and ESCs 
Nanog’s role in embryonic development and in stabilising ESC pluripotency has 
been investigated by a number of different research groups. In mice, Nanog 
knockout embryos (Nanog-/-) were found to contain highly disorganised 
extraembryonic tissues and did not develop beyond implantation (Mitsui et al., 
2003). These embryos lacked a functional epiblast cell population suggesting that 
Nanog is specifically required to demarcate and maintain the pluripotent epiblast. 
Interestingly, the hypoblast also failed to form within the mutant embryos which 
would suggest Nanog plays an additional role in potentiating the specification of 
the hypoblast. By contrast, mice heterozygous for Nanog (Nanog+/-) were normal 
in gross appearance and were fertile. Because of the mutant epiblast, the 
researchers were unable to derive an ESC line from the Nanog-/- embryo. 
However, they were able to engineer Nanog-/- ESCs in vitro via gene targeting, 
but these cell quickly differentiated into extraembryonic endoderm.  
 
A series of subsequent studies have further confirmed that a reduction in Nanog 
expression increases a cells propensity to differentiate (Chambers et al., 2007, 
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Hatano et al., 2005, Ivanova et al., 2006). Nanog+/- ESCs, which produce half the 
amount of Nanog compared with wild type ESCs, were found to readily 
differentiate into a variety of embryonic lineages including mesoderm, endoderm, 
and ectoderm (Hatano et al., 2005). Moreover, when exogenous Nanog was added 
to the Nanog+/- ESC cultures, the undifferentiated pluripotent state was 
successfully restored. 
 
In contrast to earlier knockout studies (Mitsui et al., 2003, Hatano et al., 2005), 
Chambers et al. reported that Nanog-/- ESCs were still capable of infinite self-
renewal despite being more prone to differentiation (Chambers et al., 2007). This 
would suggest that a reduction in Nanog does not strictly commit ESCs to 
differentiate. Furthermore, even though the Nanog-/- ESC colonies exhibited 
slower proliferation and contained prominent cytoplasmic protrusions, these cells 
were still capable of forming teratomas when transplanted under the mouse 
kidney capsule. The group also discovered a novel function of Nanog in PGC 
development as PGCs failed to mature upon reaching the genital ridge in Nanog-/- 
embryos. This would suggest that Nanog is specifically required to switch on the 
germ cell developmental program.  
 
Culturing ESCs in the presence of retinoic acid can cause cells to differentiate. 
However, the differentiating effect of retinoic acid was found to be overcome by 
overexpression of Nanog (Loh et al., 2006). Based on this observation and the 
results of their own knockout studies, Chambers et al. have proposed a basic 
model explaining how Nanog acts to specify and maintain pluripotency (Fig. 4). 
The fluctuation of Nanog expression allows pluripotent stem cells to exist into 
two separate states. When Nanog expression is high, the cell is in a pristine naïve 
state of pluripotency and is unresponsive to differentiation cues. That same cell 
can then enter into a transient state of low Nanog expression where it exists in a 
‘primed’ state of pluripotency. This low Nanog state provides the cell with the 
opportunity to respond to any intrinsic or extrinsic differentiation signals, also 
known as ‘lineage priming’. However, this primed state of pluripotency is 
reversible and subsequent reversion to high Nanog levels brings the cell back to 
naïve pluripotency. When Nanog is completely absent, cell reversion is no longer 
possible but the cell can still self-renew assuming pluripotent promoting 
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conditions are maintained. By contrast, if Nanog is overexpressed, the low Nanog 
transitional state does not exist and the cells do not have the opportunity to 
respond to differentiation signals and thus exist in a continuous state of self-
renewal. 
 
 
Fig. 4. Chambers et al. model of how Nanog acts to specify and maintain 
pluripotency. This model shows how Nanog expression levels dictate a cell’s 
differentiation and self-renewal status. Curved arrows represent the potential for self-
renewal (Adapted from Chambers et al., 2007) 
 
Exactly how Nanog functions to regulate the pluripotent state is still under 
investigation. The combined use of chromatin immunoprecipitation (ChIP) and 
microarrays have been particularly helpful in unravelling the various gene targets 
of Nanog (Boyer et al., 2005, Loh et al., 2006). In mouse ESCs, Nanog was found 
to bind to 3006 different regions of DNA (Loh et al., 2006). Subsequent 
modulation of Nanog levels together with microarray expression profiling 
revealed that the major downstream targets activated by Nanog were associated 
with pluripotency and self-renewal processes (e.g. Oct4, Sox2, FoxD3). The 
majority of genes downregulated by Nanog were affiliated with lineage 
commitment, in particular transcription factors which induce differentiation into 
the three primary germ lineages (e.g. Hoxb1, Pax6, Lhy5).  
 
Currently, it is still unclear how Nanog binding can activate some promoters 
whilst repress others, but it is likely additional co-factors are involved (Boyer et 
al., 2005). Indeed, Nanog binding has been found to facilitate the cooperative 
binding of additional pluripotency factors to the same target. For example, Nanog 
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binding to the Xist promoter results in exposure of the Oct4 and Sox2 binding 
motifs, allowing them to subsequently bind and act together to repress 
transcription (Navarro & Avner, 2009). 
 
In comparison to murine Nanog, characterisation of bovine NANOG is still in its 
infancy. However, preliminary research does suggest that NANOG expression in 
cattle closely resembles that of the mouse model. On the mRNA level, NANOG 
was found to be restricted to the ICM in day 7 and day 8 bovine blastocysts 
(Harris et al., 2013, McLean et al., 2014). Similarly, the NANOG protein was 
found to be expressed initially within a few cells of the ICM before becoming 
restricted to the epiblast in day 8 blastocysts (Kuijk et al., 2012). By contrast, 
expression of NANOG in porcine (pig) embryos was not detectable until day 10 
(Alberio et al., 2010) suggesting that subtle differences do exist even within 
livestock animals. 
 
1.4 Mbd3 and the NuRD Complex 
Whilst a lot of research has focused on the transcriptional network of pluripotency, 
considerably less attention has been paid to the epigenetic regulation of these 
factors. However, one epigenetic protein that has recently been making headlines 
in the stem cell community because of its influential role in lineage commitment 
and pluripotency is the methyl binding domain protein 3 (Mbd3). Not only has 
this protein been found to be essential for early embryonic development, it also 
seems to be intimately involved in the efficiency of induced pluripotent stem cell 
generation. The following section will summarise what is known about Mbd3 
with regard to its structure and function in mice. A brief overview of induced 
pluripotent stem cells will then be provided highlighting the controversy as to 
Mbd3’s involvement. 
 
Mbd3 is an essential scaffold protein for the epigenetic repressor complex NuRD 
(nucleosome remodelling and histone deacetylation). Without Mbd3, the NuRD 
complex fails to assemble, resulting in embryonic lethality (Kaji et al., 2006). 
Mbd3 expression is strictly nuclear and is initially downregulated during embryo 
cleavage, but reappears at the morula stage where it continues to be expressed 
ubiquitously in all somatic tissues (Kaji et al., 2007). Mbd3 is part of a small 
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family of nuclear proteins, all of which contain a methyl-CpG binding domain. 
However, unlike other MBD proteins, Mbd3 does not bind directly to methylated 
DNA (Menafra & Stunnenberg, 2014). 
 
NuRD is an abundant co-repressor complex that is broadly conserved throughout 
the animal kingdom (McDonel et al., 2008). Structurally, NuRD is composed of 
six core subunits, two of which possess enzymatic activity (Fig. 5). The Hdac1/2 
subunit functions as a histone deacetylase while the Mi-2β subunit is involved in 
chromatin remodelling. Within the NuRD complex, Mbd3 is sometimes replaced 
by its related protein Mbd2. Mbd2, however, is not essential for embryonic 
development and is far less abundant (Hendrich et al., 2001) 
 
 
 
 
Fig. 5. Structure of the nucleosome remodelling and deacetylation (NuRD) complex. 
The NuRD complex is composed of six core subunits. The principle subunit is the Mi-2β 
chromatin remodelling subunit, which is complexed with a metastasis-associated protein 
(Mta1, Mta2 or Mta3) and a methyl binding domain protein (Mbd2 or Mbd3). NuRD also 
contains a histone deacetylase (Hdac) complex which consists of Hdac1, Hdac2, and 
retinoblastoma binding proteins (Rbbp) 4 and 7. Gata2a and Gata2b are also commonly 
detected in NuRD purifications. (Adapted from McDonel et al., 2008) 
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1.4.1 Function of the NuRD Complex 
Any major change in gene expression, such as the switch between a pluripotent 
state and differentiated state, requires extensive epigenetic alterations (Liang & 
Zhang, 2013). In ESCs, the chromatin is largely in an open transcriptional state 
(euchromatin) which is what gives these cells their wide differentiation potential. 
In contrast, somatic cells which have already committed to a specific lineage, 
have much more condensed chromatin (heterochromatin) (Meshorer & Misteli, 
2006).  
 
The ATP-dependent chromatin remodelling complex NuRD is capable of 
regulating local changes in chromatin and therefore plays an important role in cell 
fate changes. Specifically, it functions as a transcriptional repressor, binding to 
methylated DNA sequences and mediating heterochromatin formation through 
histone modification (Luo et al., 2013).  
  
Histones are nuclear proteins which wrap around DNA and package it into 
chromatin (Gelato & Fischle, 2008). Histones have a covalently modifiable N-
terminal tail which can incur nine different post-translational modifications, most 
commonly, acetylation, methylation, and phosphorylation (Vinci, 2011). These 
modifications influence chromatin condensation and consequently DNA 
accessibility to transcription factors and DNA binding proteins. Histone 
acetylation on lysine residues is generally associated with transcriptional 
activation due to the acetyl groups’ ability to neutralise the positively charged 
histones (Vinci, 2011). Consequently, the electrostatic bonding between histones 
and DNA is reduced and the chromatin can open up allowing transcription factors 
to gain access to their target sites.  
 
The function of the histone deacetylase subunit of the NuRD complex, is to 
remove the acetyl groups from the histone proteins, and in doing so, return the 
chromatin back to a closed heterochromatin state. To gain access to the histone 
tail, the NuRD complex first has to remodel the chromatin, which is carried out by 
the Mi-2β subunit. The NuRD complex thus acts as a cohesive unit in repressing 
transcription, and is also known to cooperate with a number of additional 
repressor complexes (Reynolds et al., 2012b). 
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1.4.2 Modulation of Mbd3 in Embryos and ESCs 
In murine embryos, Mbd3 was found to play a prominent role in regulating cell 
lineage specification (Kaji et al., 2007). By day 4.5, Mbd3-/- embryos 
morphologically resemble their wild-type counterparts, with clearly segregated 
trophectoderm, epiblast, and hypoblast tissue. However, following implantation, 
Mbd3-/- ICM cells fail to expand into late epiblast and continue to express the 
hypoblast marker, Gata4. Various other embryonic lineages, such as the 
extraembryonic ectoderm, and visceral endoderm, also fail to develop 
appropriately resulting in embryo death. Evidently, no ESC lines were derived 
from Mbd3-/- embryos suggesting Mbd3 is important for the proliferation of 
epiblast cells in vitro. However, Mbd3-/- ESCs could be generated by gene 
targeting, suggesting Mbd3 is not required for ESCs to self-renew. Genetic 
analysis of the mutant ICMs discovered several lineage-specific markers were 
significantly altered. Notably, Mbd3 deficiency resulted in the upregulation of 
germ cell markers, Sohlh2 and Daz1, and a down regulation of the early 
embryonic Pramel gene family, whose exact function is still unknown (Kaji et al., 
2007). 
 
In vitro, Mbd3-/- ESCs were found to express higher levels of certain pluripotency 
genes. Interestingly, the core pluripotency factors, Oct4, Sox2, and Nanog were 
not affected (Kaji et al., 2006, Reynolds et al., 2012a). Upon LIF withdrawal, 
Mbd3 deficient ESCs fail to commit to differentiation and remain in a state of 
self-renewal (Reynolds et al., 2012a). However, subsequent treatment with 
retinoic acid did lead to cell differentiation suggesting Mbd3 does not completely 
prevent differentiation. It is likely that in the absence of Mbd3, expression of self-
renewal factors can continue without inhibition by the NuRD complex. Therefore, 
when LIF is removed, which normally results in a loss of self-renewal, the higher 
expression of pluripotent genes allows Mbd3 deficient ESCs to retain their 
pluripotent state and continue to self-renew.  
 
1.4.3 Mbd3’s Role in Induced Pluripotent Stem Cell Generation 
Less than a decade ago, the stem cell community was elated after it was 
discovered that differentiated somatic cells could be fully reprogrammed back to a 
stable pluripotent state (Takahashi & Yamanaka, 2006). Previously, this had only 
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been achieved by fusing somatic cells with pre-existing pluripotent cells (Tada et 
al., 2001, Cowan et al., 2005). In a ground-breaking study, Takahashi and 
Yamanaka analysed 24 candidate genes they suspected were capable of inducing 
pluripotency in somatic cells. By screening the individual candidates one by one, 
or in combination, they discovered that a quartet of factors, when retrovirally 
transduced into mouse embryonic fibroblasts (MEFs), were capable of generating 
what they refer to as induced pluripotent stem cells (iPSCs). These four factors 
were Oct4, Sox2, Klf4, and c-Myc, more commonly referred to as the OSKM 
factors. In recognition of his contribution to the scientific community, Yamanaka 
received the 2012 Nobel Prize in physiology or medicine. 
 
Compared to ESCs, iPSCs have a remarkably similar gene expression profile, 
chromatin configuration, and likewise possess two active X chromosomes. In 
addition to inducing teratoma formation and generating germline competent 
chimeras (Takahashi & Yamanaka, 2006), iPSCs were also able to pass the most 
stringent assay for naïve pluripotency, that is, the generation of an embryo entirely 
derived from iPSCs (Boland et al., 2009, Zhao et al., 2009). 
 
To generate iPSCs the differentiated cell must pass through two distinct phases of 
molecular reprogramming (Apostolou & Hochedlinger, 2013). Firstly, the somatic 
cell must switch off its current lineage-specific gene expression program, 
shedding its former cellular identity, resulting in the generation of a partially 
reprogrammed dedifferentiated pre-iPSC intermediate. To complete the 
reprogramming process, the cell then has to switch on its endogenous pluripotent 
gene network allowing it enter into a self-sustaining naïve pluripotent state. The 
OSKM factors are fundamental for initiating the first gene expression change. 
However, once the cell has dedifferentiated, and the endogenous pluripotency 
network activated, the cells no longer need to rely on the exogenous 
reprogramming factors which consequently become silenced (Takahashi & 
Yamanaka, 2006). 
 
Unfortunately, the reprogramming process is very inefficient with anywhere 
between 0.1 and 10% of transfected cells successfully reprogramming to full 
pluripotency. The arrival at full pluripotency is typically determined by the 
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number of iPSC colonies formed that are positive for authentic pluripotency 
markers (e.g. Oct4 or Nanog). The stochastic nature of reprogramming is also a 
problem as cells proceed at different rates making the entire reprogramming 
process very difficult to monitor. Consequently, considerable research has been 
directed towards improving the efficiency of molecular reprogramming (De 
Miguel et al., 2010). 
 
Recently, Abad et al., successfully generated a secondary expression system in 
which the OSKM transgenes were already stably integrated within the mouse’s 
genome and could be switched on in an inducible manner (Abad et al., 2013). 
Administration of the antibiotic doxycycline was sufficient in activating 
ubiquitous expression of the transgenes. As expected, expression of OSKM 
throughout the animal resulted in the formation of multiple teratomas – a sign that 
reprogramming can occur in situ. The researchers then proceeded to isolate and 
characterize iPSCs from the bloodstream of the transgenic mice, which they found 
had a higher differentiation potential than in vitro produced iPSCs, capable of 
contributing to both embryonic and extraembryonic tissues in chimeras. 
 
Using a similar secondary reprogramming system, a separate group set off to 
discover which molecular factors were responsible for blocking the efficient 
generation of iPSCs (Rais et al., 2013). Given that pluripotent cells possess 
relatively open chromatin (Meshorer & Misteli, 2006), and the recent finding that 
depletion of epigenetic repressors can improve reprogramming efficiencies (Luo 
et al., 2013), Dr Jacob Hanna and colleagues carried out a loss-of-function screen 
in mice to identify which candidate repressor complexes were hindering the 
reprogramming process. Remarkably, they found that inhibition of a single 
repressor protein, Mbd3, in embryonic fibroblasts led to an almost 100% 
reprogramming efficiency, compared to only 20% in wild-type cells. Moreover, 
reprogramming was synchronised and complete within one week of OSKM 
induction and Mbd3 genetic depletion. The pluripotent potential of the Mbd3-/- 
iPSCs was validated by successful teratoma formation and generation of chimeric 
mice. On further analysis, Mbd3 was found to inhibit only the initial stage of 
reprogramming by binding, and presumably repressing, the OSKM factors. The 
authors describe the generation of iPSCs in the presence of Mbd3 like “driving a 
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car with the handbrake on.” However, depleting cells of Mbd3 releases the brake 
and allows the cells to complete their reprogramming and arrive smoothly at their 
pluripotent destination. 
 
The findings presented by Hanna’s group have now been challenged by a separate 
research group led by Dr José Silva, who just recently published results which 
suggest that Mbd3 plays a facilitative role in molecular reprogramming (Dos 
Santos et al,, 2014). Using neural stem (NS) cells, the group generated a variety of 
Mbd3 modulated cells lines, including a homozygous null line (Mbd3-/-), a 
heterozygous line (Mbd3fl/-) and a rescue cell line containing a Mbd3 transgene 
(Mbd3-/-:Mbd3). Because NS cells already express Sox2, the cell lines were 
transduced retrovirally with the remaining factors, Oct4, Klf4, and c-Myc to 
generate iPSCs. Coincidently, they discovered that Mbd3 null cells produced 
fewer iPSC colonies than wild-type or rescue lines. 
 
The apparent disagreement between these two studies is a major cause for concern. 
Differences in results could stem from the different reprogramming systems used 
to generate iPSCs, i.e. secondary system vs. retroviral induction. Furthermore, as 
the groups chose to focus on different cell types, any direct comparisons are 
difficult. It might be that Mbd3 simply behaves differently in a stem cell line (i.e. 
NS cells) as opposed to a somatic cell line (i.e. MEFs). Further research is clearly 
still required to determine the precise function of Mbd3 in molecular 
reprogramming and thus establish whether it plays an inhibitory or facilitative role 
in iPSC generation. If the removal of Mbd3 is indeed sufficient to overcome the 
reprogramming block in iPSCs, one would assume it plays a similar role in vivo 
(i.e. embryonic development). Therefore, it is theorised that removing Mbd3 
during early embryonic development may prevent differentiation of the epiblast, 
maintaining the naïve pluripotent cell population for longer, and increasing the 
likelihood of deriving authentic pluripotent ESCs. 
 
1.5 Research Rationale 
ESC derivation has so far proven non-permissive for livestock animals, which 
may in part be due to a limited understanding of pluripotency specification in 
these animals. The core pluripotency factor Nanog, has been shown to play a 
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dominant role in orchestrating the pluripotency network alongside additional core 
factors, Oct4 and Sox2 in the mouse. Importantly, unlike Oct4 and Sox2, Nanog 
expression within the embryo is solely restricted to the epiblast, the population of 
cells from which naïve pluripotent cells can be derived. As such, the expression of 
Nanog within the early embryo is considered to be a key discriminatory marker of 
naïve pluripotency.  
 
The function of NANOG in livestock animals, such as the cow, is still yet to be 
determined. At present, current livestock ESC derivation protocols are strongly 
based on what is known about pluripotency specification in rodents. However, 
development of the preimplantation embryo differs significantly between these 
two groups of animals particularly with regards to timing of key embryonic events. 
Therefore, it can be assumed that the specification and regulation of the 
transcriptional pluripotency network may also indeed differ between these 
animals.  To validate NANOG as a core pluripotency factor in cattle, it’s 
functionality in bovine embryos needs to be investigated. 
 
Similarly, the epigenetic protein, MBD3, has yet to be studied in any livestock 
species. The discovery made by Hanna’s team that removing Mbd3 can lead to 
synchronised and highly efficient conversion of MEFs to iPSCs is a dramatic new 
development for the iPSC community. However, contradictory evidence presented 
by Silva’s team, who claim Mbd3 is required for efficient molecular 
reprogramming, has now called the protein’s function into question. The murine 
embryo data does support a role of Mbd3/NuRD in developmental transitions 
suggesting that Mbd3 is an influential embryonic protein, particularly in 
regulating cell fate decisions. Because of its controversial role in molecular 
reprogramming and its necessity for embryonic development in mice, its function 
in cattle warrants particular attention.  
 
1.6 Functional Study Approaches 
Functional studies are often used to determine the precise molecular function of a 
gene in a given context. Although it might seem rather counterintuitive, one of the 
best ways of figuring out what a gene does is to monitor what happens when it is 
removed from an organism (Alberts et al., 2002). This approach is known as a 
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reverse genetic approach and typically involves the generation of knockout 
animals in which the protein-coding regions of a gene are mutated or deleted 
entirely such that it becomes inoperant (Laible & Alonso-González, 2009). 
 
Gene knockouts rely on the natural phenomenon of homologous recombination 
(HR) in which similar regions of DNA can crossover when paired up next to each 
other. Taking advantage of this system, targeting vectors can be engineered to 
contain a mutated sequence of a target gene flanked by two stretches of 
homologous sequence. Consequently, when this vector is introduced into a cell it 
can undergo HR with the endogenous target sequence removing the functional 
copy of the gene. 
 
In contrast to ESCs, the frequency of HR in primary somatic cells is very low. As 
such, the efficiency of gene knockout in farm animals, which do not yet have any 
established ESC lines, is also very low. Moreover, because of their long gestation 
time and small number of offspring, gene knockout in livestock animals is not a 
practical approach for investigating gene function. An alternative and simpler 
method, is to instead reduce the expression level of a gene via a technique known 
as RNA interference (RNAi). 
 
1.6.1 RNA Interference 
RNAi is a widespread natural phenomenon that has become a powerful new 
research tool for understanding gene function (Novena & Sharp, 2004). As its 
name suggests, RNAi involves the use of small double stranded RNA (dsRNA) 
molecules. Despite their small size, these dsRNA molecules can significantly 
knockdown the expression of a particular gene by simply preventing translation of 
complementary messenger RNA (mRNA) transcripts (Hammond, 2005). In nature, 
RNAi is commonly employed to combat viral infections, particularly in small 
eukaryotic organisms (Buchon & Vaury, 2006). RNAi is also involved in fine 
tuning gene expression for many important cell processes, such as cell growth and 
differentiation (Wilson & Dounda, 2013). 
 
Like most phenomena in science, RNAi was initially stumbled upon by accident 
by several plant biologists in 1990 (Napoli et al., 1990, van der Krol et al., 1990). 
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In an attempt to deepen the purple colour of petunias, the researchers decided to 
introduce multiple copies of a transgene responsible for purple flower 
pigmentation. However, rather unexpectedly, the transgene did not give rise to 
darker purple flowers, but instead resulted in plants with white or patchy flowers. 
Unsure what to make of this peculiar observation, they hypothesised that the 
transgene must have somehow switched off both itself as well as the endogenous 
pigmentation gene. Subsequently, it was later discovered that multiple copy 
transgenes are capable of producing small amounts of dsRNA.  
 
To confirm whether dsRNA was responsible for the dramatic gene knockdown 
observed by the plant biologists, two molecular scientists started researching the 
effect of dsRNA on nematodes. In a Nobel Prize winning experiment, Fire and 
Mello were able to show that injection of dsRNA molecules into Caenorhabditis 
elegans led to potent silencing of complementary gene transcripts (Fire et al., 
1998). Not long after, numerous other researchers began reporting the occurrence 
of dsRNA-induced silencing in various other plants and animals and it was soon 
realised that this RNA phenomena was a broadly conserved mechanism for 
genome defence and regulation (Novena & Sharp, 2004). Exploiting this system, 
scientists now have the ability to artificially engineer dsRNA molecules which 
they can use either for therapeutics or for functional gene studies. 
 
The RNAi pathway utilises various different forms of dsRNA molecules. The two 
most common forms are small interfering RNAs (siRNAs) and microRNAs 
(miRNA) which both originate from longer dsRNA precursors (Ketting, 2011). A 
siRNA is generally about 21-22 nucleotides in length and is commonly derived 
from an exogenous source, such as a virus. Biomedically, synthetic siRNAs have 
successfully been used to efficiently knockdown various target genes (Soutschek 
et al., 2004, George & Tsutsumi, 2007, Howard et al., 2008). However, because of 
their exogenous origin, their knockdown effect is only transient (Wilson & 
Dounda, 2013). By contrast, a miRNA, which is usually 19-25 nucleotides in 
length, is derived from the genome and thus can generate stable gene knockdown 
when used experimentally (Novina & Sharp, 2004).  
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The genesis of miRNAs begins in the nucleus with transcription of the primary 
miRNA transcript (pri-miRNA) by RNA polymerase II. The pri-miRNA is about 
1000 nucleotides in length and because of its self-complementarity, it can fold 
over in the middle to base pair with itself, resulting in the formation of a hairpin 
structure (Saini et al., 2007). 
 
A nuclear micro-processing enzyme, Drosha, then cleaves the pri-miRNA 
transcript to generate a 65-70 nucleotide precursor miRNA (pre-miRNA) (Kim & 
Kim, 2007). Subsequently, the pre-miRNA associates with the transport 
facilitators, Exportin 5 and RanGTP, allowing it to be exported out of the nucleus 
(Lund & Dahlberg, 2006).  
 
Once in the cytoplasm, the pre-miRNA encounters a second enzyme, Dicer, which 
as its name suggests, cuts the pre-miRNA down to its mature miRNA form. 
Similarly, siRNA precursors are also processed by Dicer so that they are of 
appropriate size for loading onto an Argonaute protein. Argonaute proteins can 
associate with both miRNAs and siRNAs and preferentially select one strand of 
the duplex for binding. The selected RNA strand, known as the guide strand, 
specifically binds to the proteins PAZ and MID domains to generate a RNA-
induced silencing complex (RISC) (MacRae et al., 2008). The other strand which 
does not get incorporated is consequently discarded (Wilson & Dounda, 2013). 
 
The guide strand within the RISC is used as a template for recognising and 
binding complementary mRNA, typically within the 3’ untranslated region (UTR) 
(Kim & Rossi, 2007). The level of complementarity between the guide strand and 
the target mRNA determines the subsequent silencing effect. If there is perfect 
complementarity, as is the case for most siRNAs, RISC binding will result in 
endonucleolytic cleavage, followed by mRNA degradation (Wilson & Dounda, 
2013). However, if the binding is not 100% complementary, a common feature of 
miRNAs, cleavage does not occur and instead the binding of RISC to mRNA 
prevents translational machinery from binding so no protein is able to be produced 
(Fig. 6). RNAi is thus an effective post-transcriptional method for silencing gene 
expression, and therefore, widely used for investigating the molecular function of 
genes. 
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Fig. 6. Biogenesis and post-transcriptional silencing model of miRNA and siRNA.  
Endogenously expressed miRNAs are transcribed in the nucleus and processed by Drosha 
into pre-miRNAs before being transported into the cytoplasm via Exportin 5. In the 
cytoplasm, pre-miRNAs or long dsRNA molecules are processed by the enzyme dicer 
into their mature miRNA or siRNA form. Consequently, one strand of the duplex 
preferentially becomes incorporated into an RNA-induced silencing complex (RISC) 
which guides the complex towards the target mRNA. Binding of the RISC to the target 
mRNA can either result in translational repression or mRNA cleavage depending, in part, 
on the degree of sequence complementarity. ORF, open reading frame. (He & Hannon, 
2004)  
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1.6.1.1 The BLOCK-iTTM Pol II miR RNAi Expression System 
To experimentally introduce miRNAs into mammalian cells, numerous groups 
have developed vector-based expression systems which allow integration within 
the genome. For example, the BLOCK-iTTM Pol II miR RNAi expression system 
supplied by Invitrogen has been specifically designed for transient or stable 
expression of pre-miRNAs in mammalian cells. For simplicity, this will hereon be 
referred to as the BLOCK-iTTM miRNA expression kit. Using the online program, 
RNAi designer (Invitrogen), scientists can input the sequence of a gene they want 
to knockdown, and the software will design a variety of suitable pre-miRNA 
sequences. The engineered pre-miRNA sequences are modelled on the structure of 
an existing endogenously expressed murine miRNA, miR-155, and are designed 
to fully complement their target.  
 
The pre-miRNA sequences can then be cloned into the 5699 bp pcDNA 6.2-
GW/EmGFP-miR plasmid supplied by the BLOCK-iTTM kit (Fig. 7).  This 
plasmid allows for dual expression of the pre-miRNA along with an emerald 
green fluorescent protein (EmGFP) marker enabling researchers to track 
expression levels. Relatively high expression levels of the plasmid is made 
possible by the constitutively active cytomegalovirus (CMV) promoter which is 
recognised by RNA Polymerase II. The plasmid also carries both a spectinomycin 
and blasticidin resistance gene to allow for prokaryotic and eukaryotic selection, 
respectively. Expression of the blasticidin resistance gene is driven by the 
synthetic EM7 promoter which is based on the bacteriophage T7 promoter. 
Following transfection of the miRNA expression plasmid into mammalian cells, 
the engineered pre-miRNAs get processed into mature miRNAs by the cell’s own 
machinery, allowing them to enter into the RNAi pathway for direct target 
cleavage.  
 
The BLOCK-ITTM miRNA expression kit also includes both a positive and 
negative pre-miRNA control. The negative miRNA control construct contains a 
pre-miRNA sequence that can form a hairpin structure and is also processed by 
the host cell’s RNAi machinery. However, the mature form of the negative control 
miRNA has no target homology to any vertebrate gene and therefore is not 
predicted to cause any knockdown effect. The positive miRNA control supplied 
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by the kit is a pre-miRNA sequence for lacZ which requires cloning into the 
pcDNA 6.2-GW/EmGFP-miR vector. A lacZ reporter plasmid is also provided. 
The lacZ gene encodes for β-galactosidase, the enzyme responsible for 
hydrolysing lactose into glucose and galactose. β-galactosidase can also hydrolyse 
the lactose analog X-gal which, in addition to forming galactose, also forms an 
insoluble blue coloured product 5,5'-dibromo-4,4'-dichloro-indigo (Macgregor et 
al., 1991). The positive BLOCK-iTTM control experiment can therefore be 
performed by cotransfecting the lacZ reporter plasmid alongside the lacZ miRNA 
plasmid and assaying for knockdown of β-galactosidase (Invitrogen, 2008). 
 
 
 
Fig. 7. Plasmid map of the BLOCK-iTTM plasmid pcDNATM6.2-GW/EmGFP-miR 
used for miRNA expression (Invitrogen). Once ligated with the pre-miRNA, the total 
plasmid size is 5759 bp. Details: Cytomegalovirus (CMV) promoter (1–588), attB1 site 
(680-704), emerald green florescence protein (EmGFP) (713–1432), forward sequencing 
primer site (1409–1428), 5’ miR flanking region (1492-1518), 3’ miR flanking region 
(1519-1563), attB2 site (1592-1616), reverse sequencing primer site (1607-1626), TK 
polyadenylation signal (1645-1916), f1 origin (2028-2456), SV40 early promoter and 
origin (2483-2791), EM7 promoter (2846-2912), blasticidin resistance gene (2913-3311), 
SV40 polyadenylation signal (3469-3599), pUC origin (3737-4410), spectinomycin 
resistance gene (4480-5490), spectinomycin promoter (5491-5624). 
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1.6.2 Protein Overexpression 
In parallel to loss-of-function approaches, such as RNAi, overexpression of a 
protein resulting in a gain-of-function can also be used to determine gene function. 
Overexpression studies are particularly useful when a gene is not usually 
expressed, or expressed at low levels. One way of increasing the expression of a 
gene is to introduce transgenic plasmids containing the gene of interest into the 
desired cell line. Once inside the cell, the plasmids gets processed by the host’s 
transcription and translation machinery resulting in high expression levels of the 
gene product. If the plasmid integrates within a transcriptionally active region of 
the genome, it can maintain stable expression. The challenge of gene 
overexpression lies in maximising the number of plasmids which can enter into a 
cell and integrate within the genome without causing cellular stress and cell death. 
Recently, a transposon-based expression system was developed which takes 
advantage of the ‘genome jumping’ nature of transposable elements. This system, 
referred to as the piggyBac system, allows for high levels of plasmid integration 
and is described in the section below. 
 
1.6.2.1 The Inducible PiggyBac Expression System. 
The key component of the piggyBac expression system is the highly efficient host 
factor independent piggyBac transposase (PBase) plasmid, pCyL43. The PBase 
facilitates chromosomal integration of transposon-containing plasmids by 
recognising a pair of inverted terminal repeat sequences (ITRs) positioned either 
side of the donor DNA. The donor DNA is then integrated into random TTAA 
sites on the chromosomal DNA via a ‘cut-and-paste’ mechanism (Ding et al., 
2005). As many as 15 copies of the plasmid can be randomly integrated 
throughout the genome within one cell (Wang et al., 2008). 
 
In some instances, overexpression of a protein can lead to cell stress and poor cell 
growth (Palomares et al., 2004). To circumvent these issues a variety of inducible 
promoter expression systems have been developed (Gossen & Bujard, 1992, No et 
al., 1996, Fussenegger et al., 2000, Weber et al., 2004). In particular, the highly 
efficient piggyBac system has been modified to allow for inducible protein 
production (Li et al., 2013). The system relies on the PBase-mediated integration 
of two transposon-containing piggyBac plasmids. The first plasmid contains the 
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gene of interest and a puromycin resistance gene which are both under the control 
of a tetracycline response element (TRE) promoter.  
 
The second plasmid carries the reverse tetracycline transactivator (rtTA) inducer 
which is constitutively expressed from a CMV promoter. In the presence of the 
antibiotic doxycycline, the rtTA undergoes a conformational change allowing it to 
bind to the TRE promoter and activate expression of the donor DNA. When 
doxycycline is removed, the rtTA can no longer bind and expression is suppressed 
(Fig. 8). Thus protein expression can be switched on or off by simply 
administering doxycycline to transfected cells. 
 
 
 
Fig. 8. The doxycycline-inducible expression system. When no doxycycline (DOX) is 
present, the reverse tetracycline transactivator (rtTA) cannot bind to the tetracycline 
response element (TRE) promoter, resulting in no transcription of the target transgene. 
Upon administration of DOX, the rtTA undergoes a conformational change allowing it to 
bind to the TRE and induce transcription of the target transgene. 
 
1.7 Research Strategy and Objectives 
The aim of this research project was to determine the feasibility of using the 
BLOCK-iTTM miRNA expression system for knockdown of the pluripotency-
related proteins NANOG and MBD3 in cattle. An outline of the research strategy 
and the specific objectives of this project are summarised below. 
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The first objective of this research project was to design a variety of different 
miRNA sequences that would be specific for either the NANOG or MBD3 mRNA 
transcript. This design process was completed online using the BLOCK-iTTM 
RNAi designer tool (Invitrogen) and the sequences were then assembled into an 
expression plasmid using the BLOCK-iTTM miRNA expression kit. 
 
Next, to determine the knockdown potential of the various designed miRNAs, the 
miRNA expression plasmids had to first be tested on somatic cell lines. For 
MBD3, which is ubiquitously expressed in somatic cells, miRNAs were tested 
using a standard bovine embryonic fibroblast (BEF) line. By contrast, NANOG is 
not expressed in somatic cell lines. Therefore, to test the knockdown potential of 
the NANOG miRNAs, a NANOG expressing somatic cell line had to first be 
generated. To generate this NANOG cell line, the inducible piggyBac expression 
system was used. 
 
To establish which miRNA induced the most potent and specific knockdown, a 
robust screening assay for MBD3 and NANOG had to be developed. Knockdown 
assays were developed to detect the expression of the mRNA transcript as well as 
the protein for both NANOG and MBD3. 
 
Additionally, the feasibility of generating a stable knockdown cell line was 
investigated with the future objective of being able to use such a line for 
producing donor cells for SCNT cloning followed by IVP of embryos. In this way, 
bovine embryos could be produced that would be deficient in either NANOG or 
MBD3 and thus the functionality of these proteins in early embryonic 
development and pluripotency could be determined. 
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All incubation periods and centrifugations were carried out at room temperature 
unless stated otherwise. All glassware and plastic tubes were autoclaved (121⁰C) 
prior to use. For mRNA work, filter pipette tips were used and water was treated 
with diethylpyrocarbonate (DEPC). Non-filtered pipette tips and milliQ water was 
used for all other research purposes at a quality of 18.2 MΩ ·cm. All solutions 
used for bacterial and mammalian cell culture were filter-sterilised and prepared 
under laminar flow. A detailed list of materials, including plasmids, sequences, 
equipment, software, and commonly used reagents can be found in the appendices.  
 
2.1 Statement of Approval 
This research project was granted Environmental Protection Authority (EPA) 
New Zealand approval under the Hazardous Substances and New Organisms 
(HZNO) Act 1998. The EPA approval number was GMOO5/ARR003. All cell 
culture work was carried out in a physical containment 2 (PC2) laboratory. 
 
2.2 Generation of miRNA Expression Plasmids 
 
2.2.2 miRNA Sequence Design 
For RNAi-mediated knockdown of NANOG and MBD3, miRNAs were designed 
that specifically targeted either the NANOG or MBD3 mRNA transcript, 
respectively. Using the National Center for Biotechnology Information (NCBI) 
nucleotide database, the NANOG and MBD3 mRNA sequences were obtained and 
their accession numbers (NANOG = NM_001025344.1, MBD3 = 
NM_001128505.1) were input into the online program, BLOCK-iTTM RNAi 
designer (Invitrogen, USA). The program then used a proprietary algorithm to 
design miRNA sequences specific for each mRNA transcript. To avoid off-target 
effects, miRNAs were designed to specifically target the open reading frame 
(ORF) as opposed to the 3’ or 5’ untranslated regions (UTRs), a common target of 
endogenous miRNAs. The top three most highly ranked miRNA sequences for 
each gene were then screened against the entire bovine genome (Genbank 
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accession number: GCA_000003205.4) to confirm their specificity using NCBI’s 
Basic Local Alignment Search Tool (BLAST). Three miRNA sequences for each 
gene were selected and ordered from Integrated DNA Technologies. The miRNA 
sequences can be found in Appendix II. 
 
2.2.3 Assembly of miRNA Oligonucleotides 
The miRNA sense and anti-sense oligonucleotides (oligos) arrived in a 
lyophilized state and were resuspended in DEPC-treated water to a final 
concentration of 1 mM. To generate miRNA expression plasmids, the BLOCK-
iTTM miRNA expression kit was used (Invitrogen, USA). Firstly, an annealing 
reaction was set up in a 600 µl Eppendorf tube and involved combining 1 µl from 
each miRNA oligo pair (sense and anti-sense) with 2 µl of 10x oligo annealing 
buffer and 16 µl of DEPC-treated water. To anneal the single-stranded miRNA 
oligo pairs, the annealing reaction was first incubated by placing on a 95⁰C 
thermomixer for 4 minutes and then cooled down to room temperature for 10 
minutes. Samples were centrifuged briefly for 5 seconds before removing 1 µl for 
a dilution series. The double-stranded (ds) oligo was firstly diluted 100-fold in 
DEPC-treated water (1 µl of 50 µM ds oligo in 99 µl of DEPC-treated water) to 
give a final concentration of 500 nm. After vortexing gently to mix, the reaction 
was then further diluted 50-fold in annealing buffer (1 µl of 500 nm ds oligo in 5 
µl of 10x annealing buffer and 44 µl  DEPC-treated water) to generate the 10 nM 
working concentration. All dilutions were stored at -20⁰C. 
 
2.2.4 Ligation of miRNA Oligonucleotides into the BLOCK-iTTM Plasmid 
The ds miRNA oligos were then ligated into the BLOCK-iTTM plasmid pcDNA 
TM6.2-GW/EmGFP-miR using the BLOCK-iTTM miRNA expression kit. To 
clone in the ds miRNA oligos, a 10 µl ligation reaction was prepared which 
included 2 µl of the linearized BLOCK-iTTM expression plasmid (5 ng/µl), 1 µl of 
ds miRNA oligo (10 nM), 2 µl of 5x ligation buffer, 1 µl of T4 DNA ligase, and 4 
µl of DEPC-treated water. The ligation reaction was mixed well by gently 
pipetting up and down then left to incubate for 5 minutes. In addition to the three 
miRNAs for each gene (NANOG and MBD3), a positive miRNA expression 
plasmid was also prepared using the lacZ ds miRNA oligo (10 nM) supplied by 
the BLOCK-iTTM miRNA expression kit. 
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2.3 Generation of the PB-TRE-NANOG Plasmid 
 
2.3.1 NANOG Fragment Design 
Because the intended target of the NANOG miRNAs is endogenously expressed 
NANOG within bovine embryos, the NANOG expression plasmid had to contain a 
100% identical mRNA sequence to the endogenous mRNA transcript. Using the 
NCBI database, the bovine NANOG mRNA sequence was obtained and the entire 
coding sequence was used to design a NANOG fragment for plasmid cloning. To 
assist with plasmid cloning, the NANOG coding sequence was flanked by a 5’ SalI 
and 3’ NotI restriction enzyme cut site, plus an additional three ‘stuffer’ 
nucleotides either side (see Appendix II for full sequence). The fragment was 
ordered using GeneArt StringsTM DNA fragments (Life Technologies, USA) and 
was resuspended in DEPC-treated water to a final concentration of 20 ng/µl and 
then stored at -20⁰C. 
 
2.3.2 TOPO-TA Ligation 
The TOPO-TA plasmid was used as an intermediary vector that the NANOG 
fragment was subcloned into for the purpose of cutting out again to generate 
‘sticky ends’ either side of the fragment. To ligate the NANOG fragment into the 
TOPO-TA plasmid, 3’ adenosine overhangs had to first be added on either side of 
the fragment. This was achieved by combining 0.5 µl of Faststart Taq DNA 
polymerase, 4 µl of Faststart 10x buffer, 0.5 µl of dATPs (10mM) with 5 µl 
milliQ water and placing on a 95⁰C thermomixer for 3 minutes. After leaving on 
ice to cool for 60 seconds, 30 µl of NANOG fragment (600ng) was added to the 
reaction and left to incubate at 72⁰C for 20 minutes. Following this, the TOPO-
TA ligation reaction was prepared using the TOPO-TA cloning® kit (Invitrogen, 
USA) which included 0.5 µl of linearized TOPO-TA plasmid backbone, 1 µl of 
salt solution, 1 µl of milliQ water, and 0.5 µl of the 3’ adenosine overhang 
NANOG fragment. A negative ligation control reaction, that did not contain the 
NANOG fragment, was also prepared. The reactions were vortexed briefly to mix, 
spun down, and then left to incubate for 3 hours. 
 
2.3.3 Inducible PiggyBac Ligation 
A ligation reaction was prepared by combining together 100 ng of linearized 
inducible piggyBac plasmid, PB-TRE (6.6 kb), 100 ng of ‘sticky ends’ NANOG 
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fragment (900 bp), 4 µl of 5x DNA ligation buffer, and 1 µl of T4 DNA ligase. A 
negative ligation control reaction was also prepared which did not contain any 
NANOG fragment. The ligation reactions were mixed gently by pipetting up and 
down and then left to incubate for 3 hours. 
 
2.4 Generation of the CMV-NANOG Plasmid 
In addition to the inducible PB-TRE-NANOG plasmid, a constitutively active 
CMV-NANOG plasmid was also generated. The commercial plasmid, pEGFP-N1 
(4.7 kb) was digested with the restriction enzymes SalI and NotI (as described in 
section 2.8) to excise the 700 bp GFP fragment. The digest reaction was then run 
on an agarose gel (section 2.9) and the 4 kb CMV backbone fragment was excised 
and purified (section 2.10). Subsequently, a ligation reaction was prepared using 
100 ng of CMV backbone, 100 ng of the ‘sticky ends’ NANOG fragment, 4 µl of 
5x DNA ligation buffer, and 1 µl of T4 DNA ligase. The ligation reactions were 
mixed gently by pipetting up and down and then left to incubate for 3 hours. 
 
2.5 Bacterial Culture and Transformation 
 
2.5.1 Transforming Bacteria 
To amplify plasmid copy numbers, plasmids were introduced into bacterial cells 
by transformation. Bacterial stocks containing 50 µl of One Shot® TOP10 
competent Escherichia coli (Invitrogen, USA) were stored at -80⁰C and were 
thawed on ice when required for transformation.  To transform the bacteria, 2 µl 
of the ligation reaction was added to one vial of bacteria and allowed to incubate 
on ice for 30 minutes.  
 
The bacterial cells were then heat shocked in a 42⁰C water bath for 30 seconds 
and then immediately placed back on ice. Subsequently, the bacteria/DNA 
mixture was combined with 250 µl of SOC medium and left to incubate in a 37⁰C 
water bath for 60 minutes. The transformed bacteria were then spread across a 
pre-warmed Luria-Bertani (LB) agar plate containing the appropriate antibiotic 
(Table 1) and placed upside down in the 37⁰C Sanyo incubator overnight. 
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Table 1. Selection antibiotics for bacterial cell culture 
Plasmid Antibiotic Source 
Working 
Concentration 
BLOCK-iTTM Spectinomycin Sigma Aldrich, Switzerland 50 µg/ml 
TOPO-TA-NANOG 
& CMV-NANOG 
Kanamycin Roche, Germany 25 µg/ml 
PB-TRE-NANOG Ampicillin Applichem, USA 50 µg/ml 
 
 
2.5.2 Selecting Bacterial Colonies 
Transformed bacterial plates were checked for colony formation the following day. 
To validate that the bacterial clones contained the plasmid of interest, four random 
colonies were selected to be grown up for a miniprep plasmid isolation. The 
bacterial colonies were transferred individually (via a pipette tip) to a test tube 
containing 3 ml of LB broth and the appropriate antibiotic (Table 1). The bacterial 
cultures were placed in the Infors HT ecotron 37⁰C incubator overnight on a 
moderate shake (150 rpm). If a larger quantity of bacteria was required (i.e. for a 
maxiprep), 1 ml of the overnight starter culture was transferred to a 1 L 
volumetric flask containing 100 ml LB broth with the appropriate antibiotic 
(Table 1) and cultured for a second night under the same conditions. 
 
2.5.3 Glycerol Freezing 
To preserve bacterial clones that contained a validated plasmid of interest, the 
bacterial culture was frozen down in a glycerol solution for long term storage. The 
glycerol stock was prepared by gently mixing 200 µl of glycerol (100%) with 200 
µl of the overnight bacterial culture in a 1.5 ml Eppendorf tube. All bacterial 
glycerol stocks were stored at -80⁰C. 
 
2.6 Plasmid Preparation 
 
2.6.1 Miniprep 
For small scale plasmid isolation (10 µg), the PureLink® Quick Plasmid DNA 
Miniprep Kit (Invitrogen, USA) was used according to the manufacturer’s 
instructions. Firstly, the overnight bacterial culture was harvested by 
centrifugation (8,000 x g, 2min). The bacterial pellet was then resuspended in 250 
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µl of resuspension buffer with RNase A. Subsequently, the bacteria was lysed by 
adding 250 µl of lysis buffer and mixed thoroughly by inverting five times. The 
lysis reaction was neutralised by adding 350 µl of precipitation buffer causing the 
denatured chromosomal DNA and proteins to precipitate. The lysate was then 
centrifuged (12,000 x g, 10min) and the resulting supernatant, containing the 
plasmid DNA, was poured into a spin column within a wash tube. To bind the 
plasmid DNA to the silica membrane, the spin column was centrifuged (12,000 x 
g, 1 min) and the flow through discarded. The column was then washed with 700 
µl of wash buffer containing ethanol and centrifuged twice more (12,000 x g, 
1min) discarding the flow through each time. The spin column was then placed 
into a sterile 1.5 ml recovery tube and 75 µl of TE buffer pH 8.0 was incubated on 
the membrane for 1 minute before centrifugation (12,000 x g, 2min) to elute the 
plasmid DNA. Plasmid DNA was stored at 4⁰C short term, or -20⁰C long term. 
 
2.6.2 Maxiprep 
For large scale plasmid isolation (600 µg), the PureLink® Quick Plasmid DNA 
Maxiprep Kit (Invitrogen, USA) was used according to the manufacturer’s 
instructions. In brief, the 100 ml overnight bacterial culture was pelleted by 
centrifugation (5,000 x g, 10min, 4⁰C). The resulting supernatant was discarded 
and the bacterial pellet was completely resuspended in 10 ml of resuspension 
buffer with RNase. The bacteria was then lysed in 10 ml lysis buffer and gently 
inverted until homogenous. After a 5 minute incubation, 10 ml of precipitation 
buffer was added to neutralise the reaction. The solution was then poured into a 
HiPure filter maxi column containing a filtration cartridge that had already been 
equilibrated with 30 ml of equilibration buffer. After allowing the solution to flow 
through, the column was washed with 30 ml of wash buffer. The tank beneath the 
column was then replaced with a 50 ml polypropylene centrifuge tube and 15 ml 
of elution buffer was added to the column to elute the plasmid DNA. 
Subsequently, 10.5 ml of isopropanol was added to precipitate the DNA which 
was then centrifuged (20,000 x g, 30min, 4⁰C). The supernatant was discarded and 
the DNA pellet was washed in 5 ml of 70% ethanol before being spun again 
(20,000 x g, 10min, 4⁰C). Excess ethanol was removed and the DNA pellet was 
left to air dry for 10 minutes before dissolving in 200 µl TE buffer. The maxiprep 
solution was transferred to a sterile 1.5 ml Eppendorf tube and stored at -20⁰C. 
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2.7 Plasmid Quantification 
The Nanodrop Spectrophotometer ND-1000 (Thermo Scientific, USA) was used 
to measure the concentration of plasmid DNA. The machine was first calibrated 
with water and then blanked with the solution used to resuspend the DNA. 
Plasmid DNA was measured by light absorbance (A) at 260 nm using a 1 µl 
sample to give a final concentration in ng/µl. The purity of the DNA was assessed 
by dividing its A value at 260 nm by its A value at 280 nm. An A260/A280 ratio 
between 1.8 and 2.0 was considered to be of good purity for further use. 
 
2.8 Restriction Digestion 
To ensure plasmid DNA contained the target insert, it was digested with the 
appropriate restriction enzyme (Table 2). All restriction enzymes and buffers were 
supplied by New England BioLabs (USA). As a general rule, 1 µg of DNA was 
used per 1 unit of restriction enzyme in the specified 10x digest buffer, with a 
total reaction volume of 20 µl. The reaction was left to incubate in a 37⁰C water 
bath for 1 hour before being loaded onto a 1% agarose gel. 
 
Table 2. Restriction enzymes and buffers 
Restriction Enzyme Digest Buffer Cut Site 
MscI 10x NEB buffer 4 TGG^CCA 
NotI (HF) 10x cut smart buffer GC^GGCCGC 
SalI (HF) 10x cut smart buffer G^TCGAC 
 
2.9 Gel Electrophoresis 
Agarose gel electrophoresis was used to separate and analyse fragments of DNA 
by size. To separate fragments greater than 200 bp, a 1% agarose gel was used. To 
prepare the gel, 0.8 g of UltraPureTM agarose powder was combined with 80 ml of 
1x TAE buffer and heated in the microwave for approximately 60 seconds until 
completely dissolved. Once the solution had cooled down, 8 µl of SYBR® Safe 
was mixed in to enable DNA to be visualised under UV light. The gel mix was 
poured into a taped gel cast with the appropriate sample comb inserted and left for 
15 minutes to solidify. Once solid, the gel was placed into an electrophoresis tank 
containing 1x TAE buffer and the sample comb was gently removed. To 
determine the molecular size of the DNA fragments, 8 µl of 1 kb+ DNA ladder 
was loaded into the first well using a pipette. On a strip of parafilmM®, 8 µl of 
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DNA sample was mixed with 2 µl of 5x DNA loading dye and subsequently 
loaded into the adjacent wells. The electrophoresis chamber was then connected to 
the power unit and run at a constant voltage of 100V until the loading dye had run 
approximately two thirds of the way down the gel. The gel was then removed 
from the gel cast and visualised on the BioRad Gel Doc UV Imager and analysed 
using Quantity One software (BioRad, USA). 
 
2.10 Gel Extraction and Purification 
The Wizard® SV Gel and PCR Clean-Up System Kit (Promega, USA) was used 
to extract and purify DNA from an agarose gel. Firstly, the gel was transferred to 
an ultraviolet (UV) light box and exposed briefly to identify the desired band 
which was quickly excised using a sterile scalpel blade. The isolated gel piece was 
then weighed and placed into a 1.5 ml Eppendorf tube. To solubilise the agarose, 
an equal volume of membrane binding solution was added to the tube which was 
placed on a 60⁰C thermomixer for approximately 10 minutes. Once dissolved, the 
solution was poured into a SV mini column and left to incubate for 1 minute so 
that the DNA could bind to the column membrane. The mini column was then 
spun on max speed (14,000 x g, 1min) and the resulting flow through was 
discarded. Subsequently, the column was washed twice with wash buffer to 
remove any residual salts or impurities within the membrane. The first wash 
involved adding 700 µl of wash buffer followed by centrifugation at max speed 
for 1 minute. Whereas, the second wash step used 500 µl and was centrifuged on 
max speed for 5 minutes. After discarding the flow through, the column was then 
spun dry (14,000 x g, 1min) to remove any excess ethanol leftover from the wash 
steps. To elute the DNA, the column was placed within a 1.5 ml Eppendorf tube 
and incubated with 50 µl of nuclease-free water for 1 minute before being spun at 
max speed (14,000 x g, 1 min). The resulting flow through containing the purified 
DNA of interest was then measured by the Nanodrop and stored at -20⁰C. 
 
2.11 DNA Sequencing 
 
2.11.1 Sequencing Preparation 
To verify that the target insert had not undergone any point mutations during the 
plasmid preparation steps, plasmid DNA was sent to Massey Genome Service, 
New Zealand for sequencing. Each sequencing reaction was made up to a final 
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volume of 20 µl and contained 300 ng of plasmid DNA and 4 pM of forward 
and/or reverse sequencing primer (Table 3). 
 
Table 3. DNA sequencing primers 
Primer Name Sequence (5’-3’) 
BLOCK-ITTM F: GGCATGGACGAGCTGTACAA 
R: CTCTAGATCAACCACTTTGT 
M13 F: CCCAGTCACGACGTTGTAAAACG 
R: AGCGGATAACAATTTCACACAGG 
NANOG + RE F: ATTGTCGACATGAGTGTGGGCCCAGCTT 
R: ACAGCCTGAAGATTTGTAAGCGGCCGCATA 
 
 
2.11.2 Sequencing Analysis 
Sequencing results were opened and analysed using the bioinformatics software 
Geneious, version 7 (Biomatter Ltd, New Zealand). Any mismatches in sequence 
were investigated further by analysing the chromatogram using the program 
Chromas Lite, version 2.01 (Technekysium, Australia). Any plasmid that did 
contain a mutation was discarded and not used for transfection experiments. 
 
2.12 Mammalian Cell Culture 
To prevent contamination with bacteria, fungi, mycoplasma, or other cell lines, 
mammalian cell culture work was carried out under sterile laminar flow hoods 
that were routinely wiped before and after use with 70% ethanol. Bovine cell lines 
and HeLa cells were cultured in 5% CO2 water jacketed incubators set at 38.5⁰C 
or 37⁰C, respectively. Base media was prepared when required and consisted of 
DMEM/F12 + glutamax media (GIBCO, USA) supplemented with 10% fetal calf 
serum (FCS). Base media, phosphate buffered saline (PBS), 0.25% trypsin, and 
TrypLETM Express were always pre-warmed to 37⁰C just prior to use. 
 
2.12.1 Thawing Cells 
Frozen aliquots of cells were stored in cryovials in a liquid nitrogen tank (-196⁰C). 
When required, a cryovial containing the desired cell line was transferred directly 
from liquid nitrogen to the 37⁰C water bath and thawed until only a small ice 
clump was remaining. Thawed cells were then gently added to a 15 ml Falcon 
tube containing 9 ml of pre-warmed base media and pelleted by centrifugation 
(1,000 rpm, 3 min) on the Biofuge fresco (Heraeus, Germany). The supernatant 
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was aspirated and the cell pellet was gently resuspended in the appropriate volume 
of base media before transferring to the appropriate tissue culture dish. 
 
2.12.2 Cell Count 
Cell counts were performed to gain an estimate on the number of cells suspended 
in base media to ensure seeding was done at the optimal density. To perform a cell 
count, the suspended cell solution was mixed gently to prevent cells settling at the 
bottom of the tube. Two 10 µl aliquots were then taken and loaded either side of a 
hematocytometer. Under the Nikon light microscope, cells within the 5 counting 
squares were counted and the total concentration of cells was calculated using 
Equation 1. 
 
Equation 1. Estimation of cell concentration using a hematocytometer 
 
no. of cells counted 
x  total vol of cell suspension (ml)  x  10,000 =  total no. of cells 
5 
 
 
2.12.3 Passaging Cells 
Cells were passaged during the log phase of growth from dishes that were around 
70 - 90% confluent. Base media was aspirated and cells were washed briefly in 
PBS to remove any residual dead cells. To lift off adherent cell cultures, a 
minimal layer of 0.25% trypsin was added to just cover the tissue culture plate 
which was then left to incubate at 37⁰C for 3 to 5 minutes. After checking under 
the microscope that the cells had detached from the surface, cell clumps were 
broken up by gently pipetting the cell solution up and down. The resuspended 
cells were then transferred to a 15 ml Falcon tube and 9 ml of fresh base media 
was gently mixed in to deactivate the trypsin. Two 10 µl aliquots were then taken 
and loaded either side of a haemocytometer for a cell count. Meanwhile, the 
trypsinised cells were pelleted by centrifugation (1,000 rpm, 3 min) and the 
resulting supernatant was removed by aspiration. Finally, the cell pellet was 
resuspended in the appropriate volume of base media and seeded onto fresh 
culture dishes. 
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2.12.4 Freezing Cells 
To keep the passage number of cells low, cultures that were no longer 
immediately required were frozen down and stored in liquid nitrogen. Prior to 
freezing, a cryoprotectant solution was prepared which consisted of FCS + 20% 
DMSO. Cells were harvested in 0.25% trypsin and diluted in 9 ml of base media. 
A cell count was performed while the cells were pelleted by centrifugation (1,000 
rpm, 3 min). The cell pellet was then resuspended in base media to a 
concentration of 2 x 106 cells per ml. An equal volume of cryoprotectant solution 
was then added slowly to avoid chemical shock bringing the concentration down 
to 1 x 106 cells per ml. The cell solution was then split across the required number 
of cryovials, typically in 1 ml aliquots. Cryovials were placed in a Mr FrostyTM 
freezing container filled with 100% isopropanol and placed at -80⁰C to begin the 
slow freezing process of -1 degree per minute. The next day, cryovials were 
transferred directly into liquid nitrogen for long term storage. 
 
2.13 Transfection of Mammalian Cells 
Transfection is the process by which plasmid DNA is introduced into eukaryotic 
cells. The majority of plasmid DNA will remain within the cytoplasm and will 
only be expressed a few days before being degraded or diluted by cell division 
(Recillas-Targa, 2006). However, a small percentage of plasmids will integrate 
into the host genome allowing stable expression assuming it has integrated into a 
transcriptionally active region (Kim & Eberwine, 2010).  
 
2.13.1 Lipofectamine® LTX 
Lipofectamine® LTX is a lipid-based transfection protocol that can generate 
relatively high transfection efficiencies whilst also being gentle on the cells 
(Invitrogen, USA). The cationic lipid reagent LTX supplied by the kit 
spontaneously forms condensed lipid complexes with DNA by binding to the 
negatively charged phosphate backbone. The complexes are then believed to 
interact with the cell membrane allowing for endocytosis and subsequent release 
within the cytoplasm (Chesnoy & Huang, 2000). 
 
The number of cells required for transfection varied depending on the subsequent 
cell analysis.  Similarly, the Lipofectamine® reagent volumes also varied 
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depending on the number of cells being transfected. The appropriate reagent 
volumes per culture dish size are represented in Table 4. 
 
Table 4. Lipofectamine® LTX component amounts for different size culture dishes 
Component 96-well 4-well 12-well 3 cm 6 cm 10 cm 
Adherent cells 1 x 104 1 x 105 2 x 105 5 x 105 2 x 106 4 x 106 
Opti-MEM medium 17.5 µl 100 µl 200 µl 500 µl 1 ml 3 ml 
Plasmid DNA 0.1 µg 0.5 µg 1 µg  2.5 µg 5 µg 15 µg 
PLUSTM reagent 0.1 µl 0.5 µl 1 µl 2.5 µl 5 µl 15 µl 
Lipofectamine® LTX 0.3 µl 1.25 µl 2.5 µl 6.25 µl 12.5 µl 37.5 µl 
 
 
The day before transfection, cells were seeded onto the required number of culture 
dishes so that they would be around 60-80% confluent at the time of transfection. 
The following day, base media was refreshed on each culture dish. To prepare the 
lipid complexes for transfection, plasmid DNA was firstly added to a 1.5 ml 
Eppendorf tube and diluted with opti-MEM reduced serum media. To boost 
transfection efficiencies, the diluted DNA solution was then gently mixed with the 
PLUSTM reagent and left to incubate for 5 minutes. Subsequently, DNA-lipid 
complexes were formed by mixing in the specified volume of LTX reagent and 
incubating for 30 minutes. After the incubation, the newly formed DNA-lipid 
complexes were added dropwise to the appropriate culture dish which were 
swirled gently before placing back into the respective incubator to culture for 24 
hours. 
 
2.13.2 NeonTM Electroporation 
NeonTM electroporation is an alternative transfection protocol which can generate 
even higher transfection efficiencies than Lipofectamine® LTX but at a cost of 
reduced cell viability (Invitrogen, USA). Cells to be transfected are resuspended 
in a conductive solution which is then submitted to a brief electrical pulse. At the 
optimal voltage, this electrical pulse disturbs the phospholipid bilayer of the 
membrane causing temporary pores to form. Plasmid DNA is then presumed to be 
driven through the pores and into the cytoplasm via an electrostatic attraction 
(Shigekawa & Dower, 1998). 
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Similarly to the Lipofectamine® LTX protocol, the NeonTM electroporation 
protocol required cells to be 70-90% confluent on the day of transfection. Cells 
were washed briefly in PBS and trypsinised in 0.25% trypsin for 3 minutes at 
37⁰C. The trypsin/cell solution was then transferred to a 15 ml Falcon tube and 
diluted in base media to 10 ml. Two 10 µl aliquots were then taken for a cell count 
whilst cells were pelleted by centrifugation (1,000 rpm, 3min). The resulting 
supernatant was aspirated away and the cell pellet was washed in 10 ml of PBS. 
At this point, 1 x 106 cells were transferred to a separate 15 ml Falcon tube, 
pelleted, resuspended in 5 ml media, and seeded onto a 6cm 0.1% gelatin coated 
culture dish containing 3 round 0.78 cm2 glass coverslips. These cells were then 
left to culture in the bovine incubator and acted as the non-transfected control. 
Meanwhile, the remaining cells in PBS were pelleted, and then resuspended in 
NeonTM R buffer at a density of 1.0 x 107 cells/ml. 
 
To transfect 1 million cells, 100 µl of resuspended cell solution was transferred to 
a 1.5 ml Eppendorf tube containing 5 µg of plasmid DNA and stored on ice. 
Using NeonTM 100µl pipette tips, the DNA/cell solution was carefully pipetted up 
making sure no air bubbles formed as this can cause arcing during electroporation. 
The NeonTM pipette was then inserted vertically into the NeonTM pipette station. 
To initiate electroporation, the appropriate electroporation protocol was selected 
on the NeonTM machine (Table 5). Once complete, the NeonTM pipette was 
removed from the NeonTM pipette station and the cell solution was immediately 
transferred to a 6 cm 0.1% gelatin coated culture dish containing pre-warmed base 
media and three glass coverslips. Transfected cells were then left to culture in the 
appropriate incubator for 24 hours. 
 
Table 5. NeonTM electroporation protocols 
Protocol Pulse Voltage Pulse Width Pulse Number 
Bovine Cells 1500 V 20 ms 1 
HeLa Cells 1005 V 35 ms 2 
 
2.14 Generation of Clonal Mammalian Cell Lines 
Approximately 48 hours post-transfection, base media was refreshed on all culture 
dishes and the appropriate selection antibiotic was added (Table 6). Selection 
media was refreshed every 48 hours and selection plates were monitored daily for 
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colony formation. A non-transfected control dish or the pMAX dish was used as a 
negative selection control. Cell colonies were typically picked 8 – 10 days into 
selection. Colonies were chosen only if they contained dividing cells and were far 
enough away from neighbouring cell colonies. After marking the cell colonies 
with ink on the Nikon light microscope, base media was removed and the dishes 
were washed twice with PBS to remove any residual dead cells. Cloning rings 
coated on the base with Vaseline were then placed over top of each marked 
colony and 40 µl of TrypLETM Express, a synthetic gentler alternative to trypsin, 
was added inside and incubated for 3 minutes at 37⁰C. The selection dishes were 
then gently smacked down on the bench to help dislodge any cells still attached. 
The TrypLETM Express was then diluted in 100 µl of base media and pipetted up 
and down 5 times before transferring to a 0.1% gelatin-coated 48-well plate 
containing an additional 400 µl of base media supplemented with the selection 
antibiotic.  
 
Table 6. Selection antibiotics for mammalian cell culture 
Plasmid Antibiotic Source Working Conc 
BLOCK-iTTM Blasticidin  Invitrogen, USA 10 µg/ml 
PB-TRE-NANOG Puromycin Sigma Aldrich, Switzerland   1 µg/ml 
 
 
Cell clones were then left to culture in the appropriate incubator until they reached 
80% confluence, at which point they were passaged onto a 12-well plate. Clones 
were sequentially passaged onto larger culture dishes until they reached 80% 
confluence on a 3 cm culture dish. At this point cells were harvested for 
characterisation of transgene expression and freezing. 
 
2.15 RNA Extraction 
The ZyGEM (New Zealand) RNA extraction kit, RNAGem Tissue, was used to 
rapidly isolate total RNA from mammalian cell cultures. Mammalian cells were 
harvested and resuspended in 50 µl of RNAGEM master mix solution composed 
of 1 µl RNAGem, 5 µl SILVER buffer and 44 µl of DEPC-treated water. Once 
resuspended, the solution was transferred to a 1.5ml Eppendorf tube, vortexed 
briefly and spun down in a minicentrifuge. The reaction was then incubated for 10 
minutes at 75°C to activate the enzyme, RNAGem. Afterwards, the reaction was 
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placed back on ice and 2 µl of DNase in 5 µl of DNase buffer was added to the 
reaction, vortexed briefly and spun down. To activate the DNase, the reaction was 
incubated at 37⁰C for 5 minutes followed by 5 minutes at 75⁰C to deactivate the 
enzyme. After placing back onto ice, 5.7 µl of TE buffer was added to the reaction 
and spun down. A 9 µl aliquot of reaction mix was then taken for cDNA synthesis 
while the remaining RNA reaction was stored at -80⁰C. 
 
2.16 Complementary DNA Synthesis 
To analyse mRNA expression, mRNA had to first be converted to cDNA. The 
reaction was prepared by adding 1 µl of dNTP mix and 0.5 µl of random hexamer 
primers to 9 µl of the RNA extract. The reaction was then incubated at 65⁰C for 5 
minutes to denature secondary RNA structures before plunging into ice for 1 
minute to allow the random hexamer primers to bind. Meanwhile, a cDNA master 
mix was prepared which was composed of 4 µl First-Strand 5x buffer buffer, 4 µl 
of MgCl2, 1 µl of RNaseOUT
TM, and 1 µl of SuperScriptTM III reverse 
transcriptase (RT). The cDNA master mix was then added to the reaction mix, 
vortexed briefly and spun down. A RT negative reaction was also prepared in 
which 1 µl of DEPC-treated water was added in place of SuperScriptTM III RT. 
The reactions were then placed into the Eppendorf mastercycler gradient PCR 
machine and run on the cDNA synthesis program (25⁰C 10 min, 50⁰C 50 min, 
80⁰C 5 min, hold at 4⁰C). Once complete, cDNA samples were stored at -20⁰C.  
 
2.17 Messenger RNA Quantification 
 
2.17.1 Primer Design 
Primers that were used to amplify the gene of interest were designed using the 
NCBI nucleotide database (Table 7). Where possible, primers were designed 
under the following criteria; i) product length between 170 – 230 nucleotides, ii) a 
melting temperature (Tm) between 57 and 63⁰C, and iii) spans exon-exon 
junctions. Selected primer pairs were ordered from Integrated DNA Technologies 
and arrived in a lyophilized state. After a brief spin down, primers were 
resuspended in DEPC-treated water to a stock concentration of 1mM. To form a 
10µM working concentration, 1 µl of forward and 1 µl of reverse primer was 
combined with 198 µl of DEPC-treated water. Working concentrations of primers 
were stored at -20⁰C while primer stocks were kept at -80⁰C. 
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Table 7. PCR primers 
Primer Sequence (5’-3’) Tm (⁰C) Amplicon 
Size (bp) 
18S F: GACTCATTGGCCCTGTAATTGGAATGAGTC 
R: GCTGCTGGCACCAGACTTG 
80 87 
GFP F: CCGACCACATGAAGCAGCACGAC 
R: TCACGAACTCCAGCAGGACCAT 
 
87   449 
MBD3 F: GCACGGGCAAGATGCTAATG 
R: TCGCTCTTCACCTTGTTGCT 
86 184 
NANOG F: CACCCATGCCTGAAGAAAGT 
R: TGCATTTGCTGGAGACTGAG 
83 295 
 
2.17.2 Standard Curve Generation 
To enable relative mRNA quantification, standard curves for primer pairs had to 
first be generated. This involved preparing a series of log dilutions (1 to 
1/1,000,000) using a purified gel extract of the gene of interest. A quantitative 
PCR reaction was prepared and run as described in section 2.17.3 using 2 µl of the 
serial dilution as the template The lower dilutions (1/10 to 1/1000) were run in 
triplicate while the higher dilutions (1/10,000 to 1/1,000,000) were run in 
quadruplicate to account for sensitivity bias. Standard curve information was 
exported and graphed in Microsoft Excel. A standard curve was only used for 
quantification equations of cDNA sample reactions if it had an amplification 
efficiency between 1.8 and 2. 
 
2.17.3 Quantitative PCR 
Quantitative PCR (qPCR) was used to quantify gene expression, in particular to 
assay for NANOG or MBD3 mRNA knockdown. Reactions were prepared in 
LightCycler® glass capillaries with a total volume of 10 µl. The required number 
of capillaries were first arranged in a capillary box using sterile tweezers and left 
to chill at 4⁰C while the reaction master mix was prepared. All reagents were 
thawed on ice and spun down briefly using a minicentrifuge. The Takara Bio 
SYBR® Ex Taq qPCR master mix was used for mRNA quantification and 
included the fluorescent DNA intercalating reagent, SYBR® green I. 
 
The reaction master mix consisted of 5 µl of Takara master mix, 0.8 µl of 
combined forward & reverse primer (10µM), and 2.2 µl of DEPC-treated water, 
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per sample. After vortexing to mix and a brief spin down, 8 µl of reaction master 
mix was added to the pre-chilled glass capillaries followed by 2 µl of the 
respective cDNA sample. The capillaries were then sealed carefully using the 
capping device. 
 
Alongside the cDNA samples, a positive template control (PTC) and a negative 
template control (NTC) were also set up to account for reaction success and 
contamination, respectively. The NTC contained 2 µl of DEPC-treated water in 
place of cDNA, while the PTC contained a 1/100 dilution of a purified gel extract 
of the gene of interest. Additionally, the RT negative was also included in each 
run to ensure there was no genomic DNA contamination from the cDNA synthesis 
reaction. 
 
The reaction capillaries were then gently slotted into a capillary carousel and spun 
down using the LC Carousel Centrifuge 2.0 (3,000g, 10 sec). Any volume 
discrepancies were taken note of before fitting the carousel in the LightCycler 
machine. Using LightCycler® software, the reaction template described in Table 
8 was selected. 
 
Table 8. LightCycler® reaction template for qPCR 
Step Temperature (⁰C) Duration Cycle 
Denaturation 95 10 min 1 
Amplification & Quantification 
95 20 sec 
45 60 20 sec 
72 20 sec 
Melting Curve 95 2 min 1 
Cooling 4 Hold 1 
 
 
Afterwards, results were analysed using LightCycler® software (Roche, 
Germany). A melting curve analysis was performed to verify product identity.  
Different primers produce different size amplicons with a varying GC content and 
therefore melt at a specific temperature. The NTC was not expected to produce a 
melting peak as it did not contain any cDNA template for the primers to amplify. 
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If the NTC did contain a melting peak it was either due to primer dimer formation 
or genomic DNA contamination and qPCR results were consequently discarded. 
 
Each cDNA sample was given a crossing point (CP) value which corresponded to 
the cycling number at which they passed the threshold level of fluorescence. CP 
values were exported to Microsoft Excel and relative concentrations were 
calculated using Equation 2. The value from this equation was then divided by the 
relative concentration of the housekeeping gene, 18S, to give the relative ratio. 
 
Equation 2. How to calculate the relative concentration of the gene of interest based 
on the standard curve. Slope and y intercept values were taken from the primers’ 
standard curve equation. 
 
Relative concentration = e(-(CP value – slope)/y intercept) 
 
 
2.18 Immunocytochemistry 
Immunocytochemistry (ICC) was used to detect protein on a single cell level. 
Cells that were cultured on round 0.78cm2 glass coverslips were placed, using fine 
sterile tweezers, individually into fresh 4-well plates containing PBS. After 
removing the PBS by aspiration, cell were fixed in a 4% paraformaldehyde (PFA) 
solution for 15 minutes and then washed three times in PBS. Each wash step was 
carried out for 5 minutes. Cells were then incubated in quench solution for 10 
minutes to minimise autofluorescence, washed once in PBS, and then 
permeabilised in 0.1% Triton-X for 10 minutes. After washing another two times 
in PBS, cells were incubated in the appropriate blocking solution for 60 minutes. 
Blocking solution depended on the host animal the secondary antibody was raised 
in and was either 5% donkey or 5% goat serum in PBS.  
 
During blocking, wet chambers were assembled by placing a moistened circular 
piece of filter paper into a 10 cm Petri dish and layering on top a cut of 
parafilmM®. The required amount of primary antibody dilution was then prepared 
using blocking solution as the diluent (Table 7). Subsequently, 50 µl drops of 
primary antibody dilution were placed on top of the parafilmM®, ensuring there 
was one drop per coverslip. One coverslip per treatment was reserved as a 
negative immunofluorescence control. Negative controls were assigned their own 
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wet chamber containing 50 µl drops of blocking solution without primary 
antibody. After the blocking incubation, coverslips were picked up using fine 
tweezers and flipped on top of the primary antibody/blocking solution drops. The 
wet chambers were then gently sealed shut with parafilmM® and left to incubate 
for 60 minutes, or alternatively, at 4⁰C overnight. 
 
Afterwards, coverslips were flipped cell side up into a fresh Petri dish and washed 
three times in PBS to remove any unbound primary antibody. During the washes, 
the secondary antibody/Hoechst dilution was prepared. Secondary antibodies were 
diluted as specified in Table 9 in blocking solution while the Hoechst 33342 
nuclear stain was diluted to a working concentration of 5 µg/ml. The parafilmM® 
on the wet chambers was replaced and 50 µl drops of the secondary/Hoechst 
dilution were added on top, including on the negative coverslip dish. Coverslips 
were then gently flipped onto the drops and left to incubate for 60 minute under a 
sheet of tinfoil due to light sensitivity. Following this, coverslips were removed 
from the wet chamber and washed cell side up in a fresh Petri dish three times 
with PBS and once with distilled water. Coverslips were then mounted onto 
frosted glass slides (Labserv, Ireland) using 5 µl of ProLong® Diamond antifade 
mounting medium and left to set at 4⁰C for at least 30 minutes. 
 
Table 9. Primary and secondary antibodies used for ICC 
 Dilution Source Catalog# 
Primary antibodies    
Mouse monoclonal anti-NANOG 1:100 eBioscience (USA) 14-5768 
Rabbit polyclonal anti-NANOG 1:200 Peprotech (USA) 500-P236 
Rabbit monoclonal anti-MBD3 1:250 Abcam (England) EPR9913 
 
Secondary antibodies 
   
AlexaFluor® 568 donkey anti-mouse IgG 1:1000 Invitrogen (USA) A-10037 
AlexaFluor® 488 donkey anti-rabbit IgG 1:1000 Invitrogen (USA) A-21206 
AlexaFluor® 568 goat anti-rabbit IgG 1:2000 Invitrogen (USA) A-11036 
 
Slides were visualised on the Olympus BX50 fluorescent microscope. The 
Hoechst stain was made visible by excitement at 405 nm (the blue channel), while 
red or green fluorophore-conjugated antibodies were visualised at 568 nm or 488 
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nm (red or green channel, respectively). Black and white images were captured by 
the inbuilt Spot RT3 camera, adjusting exposure times using the Spot Basic 
software (Spot Imaging Solutions, USA). Images were artificially coloured using 
the program, Image J (National Institute of Health, USA). 
 
2.19 X-Gal Staining 
X-Gal staining was used for the lacZ miRNA positive control experiment. To 
enhance the staining intensity, wash and fixing solutions were supplemented with 
2mM magnesium chloride (MgCl2) and 5 mM ethylene glycol tetraacetic acid 
(EGTA). Magnesium (Mg2+) is a cofactor for the enzyme, β-galactosidase and 
EGTA specifically chelates calcium ions (Ca2+) which would compete with Mg2+ 
for the active centre of the enzyme. In preparation for X-Gal staining, round 0.78 
cm2 glass coverslips were removed from culture dishes and placed individually 
into a 4-well plate containing the PBS wash solution. After a 5 minute PBS wash, 
cells were fixed with 4% PFA fixing solution for 15 minutes. Afterwards, cells 
were washed a further two times in PBS. During the washes, the staining solution 
was warmed to 37⁰C and then used to dilute the 20x X-Gal stock to a working 
concentration of 1 mg/ml. The X-Gal staining solution was then incubated on the 
coverslips for 24 hours at 37⁰C. 
 
Afterwards, coverslips were washed once with PBS and then incubated for 6 
minutes with Hoechst 33342 nuclear stain (5 µg/ml) under tinfoil. The coverslips 
when then washed a further two times in PBS and once in distilled water before 
being mounted onto frosted glass slides using 5 µl of Prolong® Diamond antifade 
mounting media. Glass slides were visualised on the Olympus fluorescent 
microscope, using the bright field to visualise blue β-galactosidase positive cells 
and the blue channel to visualise total cell nuclei (Hoechst stain). LacZ 
knockdown was indirectly assessed by calculating the proportion of cells that 
were positive for β-galactosidase. 
 
2.20 Statistical Analyses 
Protein and mRNA results were imported onto Microsoft Excel for data analysis. 
Replicate samples were averaged and standard deviation and standard error of the 
mean were calculated. Significance testing was performed using the Student’s T 
test with p < 0.05 indicating significance. 
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3.1 Generation of miRNA Expression Plasmids 
Specific miRNA sequences targeting either bovine NANOG or MBD3 were 
designed using Invitrogen’s online tool, RNAi designer. For each gene, the top 
three most highly ranked miRNA sequences were selected and screened against 
the entire bovine genome. Screening confirmed that the miRNA were specific for 
their target as there was no sequence homology to any additional gene regions.  
 
The BLOCK-iTTM miRNA expression kit, was used to generate the miRNA 
expression plasmids. The miRNA sequence oligos were ligated into the BLOCK-
iTTM plasmid pcDNA TM6.2-GW/EmGFP-miR. The ligation reactions were then 
immediately used to transform bacteria which were cultured overnight under 
spectinomycin selection. The transformed bacterial plates were checked for 
colony formation the following day. Transformation was successful with over 100 
colonies present on each plate and no colonies present on the negative control 
plate. Three to four bacterial clones were then randomly selected from each 
miRNA plate and were grown up overnight for a miniprep plasmid isolation.  
 
The miRNA expression constructs contain two unique MscI restriction sites, one 
within the plasmid backbone and one within the miRNA loop (Fig. 9A). To 
validate that the transformants contained the miRNA insert, plasmid minipreps 
were digested with the restriction enzyme MscI and then visualised by gel 
electrophoresis. A positive ligation was determined by the presence of two bands, 
one at 1.4 kb and one at 4.3 kb. All bacterial clones gave two bands at the 
expected molecular size (Fig. 9B). 
 
To ensure that none of the miRNA oligos had undergone any mutations during the 
preparatory reactions that could affect their specificity, plasmid minipreps (Fig. 
8B 1-26) were sent to Massey Genome Service for DNA sequencing using the 
sequencing primers provided by the BLOCK-ITTM kit. Sequencing results were 
analysed using the bioinformatics software Geneious which confirmed that all of 
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the miRNA constructs remained unchanged from the original miRNA sequence. 
Subsequently, one validated bacterial clone for each miRNA was then grown up 
for a plasmid maxiprep to ensure a large quantity of plasmid was available for 
mammalian cell transfections. 
 
 
Fig. 9. MscI restriction digestion of the miRNA expression plasmids. A. Schematic 
representation of the BLOCK-iTTM expression plasmid showing the approximate 
positions of the MscI restriction enzyme cut sites. B. Gel electropherograms documenting 
the DNA fragments present after miRNA plasmids were digested with the restriction 
enzyme MscI. Two previously validated miRNA plasmids were used as positive controls 
for the restriction digest while an undigested miRNA plasmid was used as the negative 
restriction digest control (‘neg’). 
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3.2 Generation of an Inducible NANOG Expression Plasmid 
NANOG expression is limited to the early preimplantation embryo. Therefore, a 
cell culture system had to first be engineered to express NANOG in order to 
evaluate the knockdown potential of the three NANOG miRNAs. 
 
In our laboratory, a NANOG overexpressing bovine fetal fibroblast line, EOG-
TET-NANOG, had already been engineered and was initially selected for 
screening the NANOG miRNAs. However, after several transient knockdown 
attempts which failed to show a reduction in NANOG protein or mRNA 
expression (data not shown), we discovered that the NANOG transgene within the 
line had been extensively codon-optimised during synthesis. Using Geneious 
pairwise alignment, the codon-optimised NANOG transgene was found to be only 
77% identical to the endogenous sequence of NANOG. Furthermore, none of the 
three NANOG miRNAs were able to correctly align with the codon-optimised 
NANOG transgene. Because of the degree of codon optimisation, the bovine 
overexpressing NANOG line could no longer be used for miRNA screening 
purposes and a new NANOG expressing cell line was prepared. 
 
The new NANOG transgene was designed using GeneArt StringsTM DNA 
fragment (Life Technologies, USA) and consisted of the entire endogenous 
coding sequence for bovine NANOG flanked by a 5’ SalI and 3’ NotI restriction 
enzyme cut site to facilitate cloning into the inducible piggyBac expression 
plasmid. 
 
3.2.1 TOPO-TA Plasmid Cloning and Validation 
Before the NANOG fragment could be ligated into the inducible piggyBac 
expression plasmid, PB-TRE, it was first cloned into the intermediary plasmid, 
TOPO-TA. Bacteria transformed with the TOPO-NANOG ligation reaction were 
cultured overnight under kanamycin selection. The following day, many colonies 
were present on the positive transformation plate. Four colonies were selected at 
random to be cultured on for a plasmid miniprep. 
 
To confirm that the bacterial clones contained the NANOG fragment, each 
plasmid miniprep was digested with the restriction enzymes SalI and NotI and the 
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resulting DNA fragments were visualised by gel electrophoresis. A positive 
ligation should result in three DNA fragments; one at 4 kb (TOPO backbone), one 
at 900 bp (NANOG fragment) and a smaller fragment of about 35 bp (Fig. 10A). 
The smallest fragment, which is due to a NotI site within the TOPO backbone, is 
too small to be detected on the agarose gel. Of the four bacterial clones, only one 
had correctly ligated the NANOG fragment (Fig. 10B). The validated miniprep 
(miniprep 30) was then sent away for DNA sequencing using M13 forward and 
reverse sequencing primers. Sequencing results confirmed that the NANOG insert 
remained unchanged from the original sequence. 
 
 
 
Fig. 10. SalI/NotI restriction digestion of the TOPO-NANOG plasmid. A. Schematic 
representation of the TOPO-NANOG plasmid showing the approximate positions of the 
SalI and NotI restriction enzyme cut sites. B. Gel electropherogram of a SalI/NotI 
restriction digestion showing that only one of the four bacterial TOPO-NANOG clones 
had correctly ligated the NANOG plasmid. 
 
3.2.2 PB-TRE Plasmid Cloning and Validation 
After excising the NANOG fragment from the TOPO-TA plasmid with restriction 
enzymes, the fragment now had the required SalI and NotI sticky ends required 
for cloning into the inducible PB-TRE plasmid. To isolate the NANOG fragment, 
the remaining digest reaction was run on an agarose gel. Adjacent to the DNA 
ladder, was a NANOG indicator lane. This lane contained only 5 µl of the digest 
reaction and was used to indicate where the NANOG fragment would be located. 
The adjacent three wells were filled with the remaining digest reaction and, to 
avoid DNA damage, these lanes were not exposed to UV. Thus, the 900 bp band 
in the indicator lane was excised using a scalpel blade and used to guide the 
excision of the 900 bp NANOG fragment from the unexposed lanes. 
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The unexposed NANOG fragment was extracted from the gel and quantified using 
the Nanodrop. The fragment was then ligated into the PB-TRE plasmid and 
transformed bacteria were cultured overnight under ampicillin selection. 
Transformation plates were checked for colony formation the following day and 
hundreds of colonies were present on the positive transformation plate. Six 
colonies were then randomly selected to be grown up for a plasmid miniprep. 
 
Plasmid validation was performed by digesting the plasmid minipreps with SalI 
and NotI. Positive clones should give rise to bands of 6.6 kb (PB-TRE backbone) 
and 900 bp (NANOG fragment) (Fig. 11A). Five of the six bacterial clones 
exhibited the expected pattern of bands confirming they had correctly ligated the 
NANOG fragment (Fig. 11B 32-36). In addition, two plasmid minipreps (32 and 
33) were selected for DNA sequencing. Sequencing results confirmed that the 
NANOG fragment had not undergone any mutations during the preparatory 
reactions. One of the validated bacterial clones was then grown up for a plasmid 
maxiprep ensuring a large volume of plasmid was available for transfection 
experiments. 
 
 
 
Fig. 11. SalI/NotI restriction digestion of the PB-TRE-NANOG plasmid. A. 
Schematic representation of the PB-TRE-NANOG plasmid showing the approximate 
position of the SalI and NotI restriction enzyme cut sites. B. Gel electropherogram 
showing the result of a SalI/NotI restriction digestion on PB-TRE-NANOG bacterial 
clones. All six bacterial clones gave rise to two bands, one at 6.6 kb (PB-TRE backbone) 
and one at 900 bp (NANOG fragment). 
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3.3 Generation of a NANOG Expressing Cell Line 
 
3.3.1 Bovine NANOG Cell Line 
 
Transfection of EF5-TET Cells with PB-TRE-NANOG 
The bovine EF5-TET line was selected for transfection of the NANOG expression 
plasmid because it already contained the rtTA transgene required for inducible 
expression. Using the Lipofectamine® LTX protocol, approximately 1 x 106 
passage 4 EF5-TET cells were cotransfected with 15 µg of PB-TRE-NANOG and 
3 µg of the PBase plasmid, pCyL43. As a positive transfection control, 1 x 104 
EF5-TET cells were transfected with 1 µg of the GFP plasmid, pMAX. All EF5-
TET cells were induced with 2 µg/µl of doxycycline just prior to transfection. The 
following day, the pMAX dish was visualised on the EVOS fluorescent 
microscope which confirmed around a 30% transfection efficiency. The 
transfection efficiency of the PB-TRE-NANOG dish could not be determined as 
the plasmid did not contain a fluorescent marker. The cells transfected with the 
NANOG plasmid were then split across three new 10 cm tissue culture dishes at a 
density of 2 x 105 cells per dish. The pMAX dish was passaged onto a 6 cm tissue 
culture dish at a cell density of 2 x 104. 
 
Subcloning of EF5-TET Cells 
Approximately 48 hours post-transfection, base media and doxycycline were 
refreshed on all dishes and the selection antibiotic, puromycin, was added at a 
concentration of 1 µg/ml. These media conditions were refreshed every 48 hours 
and selection plates were monitored daily for colony formation. After 8 days of 
puromycin selection, 28 distinct cell colonies on the PB-TRE-NANOG plates 
were ready for transfer to individual wells. By contrast, all cells on the negative 
selection plate pMAX had died within 4 days of selection. 
 
Cell clones were individually grown up continually in the presence of doxycycline 
and puromycin. Of the 28 colonies initially seeded onto a 48-well plate, 22 were 
passaged up onto 12-well plates and then 19 of those were passaged up to 6-well 
plates. However, the majority of cell clones which were seeded onto a 6-well plate 
flattened out, grew large processes, and stopped dividing. Only seven cell clones 
were able to grow to about 50% confluence on the 6-well plate at which point 
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they were harvested for NANOG expression analysis. Approximately 1 x 104 cells 
were taken for RNA extraction and cDNA synthesis. Another 1 x 104 cells were 
seeded onto a 4-well plate containing glass coverslips, and the remaining cells 
were cryopreserved across three cryovials. 
 
Validation of EF5-TET NANOG Clones 
To validate that the surviving clones expressed and produced NANOG, cells that 
had been seeded onto glass coverslips were stained for NANOG via ICC. Cells 
were blocked in 5% donkey serum and incubated with the Peprotech polyclonal 
rabbit NANOG antibody and the green AlexaFluor® donkey anti-rabbit 488 
secondary antibody. NANOG expression in the seven different NANOG clones 
was compared to a non-transfected EF5-TET control sample which did not 
express any NANOG. All seven NANOG clones (A4, A6, A8, B8, C1, C8, D1) 
were positive for NANOG expression which was nuclear in localisation but 
absent within the nucleoli (Fig. 12). Intensity of fluorescence was not measured 
directly but all seven clones had similar NANOG staining intensities. Importantly, 
the negative ICC control and the non-transfected EF5-TET cells were both 
negative for NANOG expression.  
 
The cDNA samples from the NANOG clones were then assayed for NANOG 
mRNA expression by qPCR. Relative NANOG concentration values were divided 
by their respective 18S values to give the relative ratio. A non-transfected EF5-
TET cDNA sample was used as a baseline comparison. Six out of the seven 
NANOG clones were found to have a significantly higher expression of NANOG 
compared to the EF5-TET parental line (Fig. 13). NANOG clone D1 had the 
largest fold difference in NANOG expression (67 fold), followed by A4 (59 fold), 
B8 (48.4 fold), and A8 (37 fold). The three remaining NANOG clones, C1, C8, 
and A6, had only slight fold differences in NANOG expression (5, 2 and 1.4 fold, 
respectively). 
 
 
 
Chapter Three: Results 
 
57 
 
 
 
Fig. 12. ICC staining for NANOG on seven stably transfected EF5-TET clones. 
Black and white images were captured using the Olympus fluorescent microscope and 
were pseudo-coloured using ImageJ. Scale bar = 50 µm  
 
 
 
Fig. 13. Quantification of NANOG mRNA expression in seven stably transfected 
EF5-TET clones. NANOG expression represents the fold difference over the parental cell 
line, EF5-TET. Error bars based on SEM for technical triplicates, *P < 0.05, ** P < 0.01 
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Immortalisation of EF5-TET NANOG Clones 
To further characterise the NANOG clones, one cryovial from each NANOG-
expressing clone was thawed and seeded onto a 96-well 0.1% gelatin-coated 
culture plate containing 2 µg/µl of doxycycline. It soon became clear that the 
NANOG clones had reached their Hayflick (cycling) limit and had begun to enter 
cellular senescence. In an attempt to preserve the NANOG clones and direct them 
to divide again, they were transfected with the oncogene plasmid pC-MYC using 
the Lipofectamine® LTX protocol. Just like the PB-TRE-NANOG plasmid, pC-
MYC also contains a TRE promoter and administration of doxycycline is required 
for the rtTA to activate expression of the C-MYC transgene as well as a 
monomeric (m) red fluorescent protein (RFP) reporter (mCherry).  
 
The NANOG clones had been cultured in doxycycline for a period of three days 
prior to pC-MYC transfection. Additionally, three adjacent wells were each 
seeded with 1 x 104 EF5-TET cells to act as transfection controls. All seven 
NANOG clone wells and the first EF5-TET well were transfected with pC-MYC 
in the presence of 2 µg/µl doxycycline. The remaining two EF5-TET wells were 
not induced with doxycycline and were transfected with either pC-MYC or the 
GFP plasmid, pMAX. 
 
The culture plate was analysed 24 hours post-transfection using the EVOS 
fluorescent microscope. The pMAX control well revealed that the transfection 
reaction had been successful with an efficiency of approximately 30%. Similarly, 
the EF5-TET well transfected with pC-MYC in the presence of doxycycline 
contained a number of RFP positive cells, with an estimated transfection 
efficiency of 30%. As expected, the non-doxycycline induced EF5-TET well 
contained no cells positive for RFP. Despite doxycycline-induction, no RFP 
positive cells were detected in any of the NANOG clone wells after transfection 
with pC-MYC (Fig. 14). Cells were continually monitored for two weeks 
following transfection but no cell growth was observed for the NANOG clones. 
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Fig. 14. Transfection efficiencies 24 hours after transfection of EF5-TET clones and 
EF5-TET controls with pC-MYC. Transfection performed using Lipofectamine® LTX. 
EF5-TET controls included a + DOX (2 µg/µl doxycycline) and – DOX (no doxycycline) 
group. Transfection efficiency was determined by the approximate proportion of RFP 
positive cells per field of view. All EF5-TET clones were negative for RFP as shown in 
the A4 + DOX column. Images were captured on the EVOS fluorescent microscope. PH 
= phase contrast. RFP = red fluorescent protein. Scale bar = 400 µm 
 
 
3.3.2 HeLa NANOG Cell Line 
 
Transfection of HeLa Cells with PB-TRE-NANOG and PB-CAG-rtTA 
To circumvent issues with cellular senescence, the PB-TRE-NANOG expression 
plasmid was instead transfected into the immortalised human cancer cell line 
HeLa. Unlike the transgenic EF5-TET line, HeLa cells did not already contain the 
rtTA which meant a triple transfection was required. Approximately 2 x 106 HeLa 
cells were transfected with PB-TRE-NANOG (7.5 kb), PB-CAG-rtTA (7 kb), and 
pCyL43 (4 kb) at either an 8:1:1 or 5:4:1 molar ratio. To boost transfection 
efficiencies, the NeonTM electroporation protocol was used over the less efficient 
Lipofectamine® LTX method. A positive transfection control was also included 
by transfecting 1 x 105 cells with 0.5 µg of pMAX. Transfected cells were induced 
2 hours post electroporation with 2 µg/µl of doxycycline to switch on expression 
of the PB-TRE-NANOG transgenes which also included the puromycin resistance 
gene. The following day (24 h post-transfection) the pMAX dish was analysed 
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under the EVOS fluorescent microscope which revealed a high transfection 
efficiency of around 70%. The transfection efficiency of the triple transfected 
HeLa dishes could not be determined due to the lack of a fluorescent reporter. 
Consistent with previous electroporation experiments, a high cell death rate of 
around 50% was observed. Transfected cells were subsequently split 1 to 4 onto 
fresh culture dishes and continually cultured in the presence of doxycycline.  
 
Subcloning of HeLa Cells 
Puromycin selection was initiated 48 hours post-transfection at a concentration of 
1 µg/ml. HeLa cells were spread thin across the culture plate but mitotically 
dividing cells were still visible. Selection media, which was also supplemented 
with doxycycline, was replenished every 48 hours. After eight days under 
selection, one small HeLa colony was discovered on one of the 5:4:1 transfection 
plate, and 3 very small colonies (<10 cells) were discovered on the 8:1:1 
transfection plates. On the 12th day of selection, all four colonies were transferred 
to a 96-well 0.1% gelatin coated plate and continually cultured in the presence of 
puromycin and doxycycline. The three small colonies from the 8:1:1 plates did 
not grow after replating and underwent apoptosis. By contrast, the larger HeLa 
colony continued to grow, albeit at a slow pace, filling up a 10 cm culture dish 
after two weeks in individual culture.  
 
Validation of the Puromycin Resistant HeLa Clone 
The 10 cm puromycin resistant HeLa clone was harvested and 1 x 104 cells were 
taken for RNA extraction and cDNA synthesis while 1 x 105 were seeded onto a 3 
cm culture dish containing glass coverslips. The remaining cells were frozen 
across three cryovials. The HeLa cells were fixed with 4% PFA on the glass 
coverslips and ICC was performed using the Peprotech rabbit polyclonal NANOG 
antibody and the AlexaFluor® 488 donkey anti-rabbit secondary antibody. A non-
transfected HeLa control was included for baseline comparisons as well as a 
negative ICC control. Both the non-transfected HeLa control and the puromycin 
resistant HeLa clone were not positive for NANOG expression (data not shown). 
In agreement with the protein data, no NANOG expression was detectable by 
qPCR analysis of the HeLa clone cDNA sample suggesting that although the cells 
were puromycin resistant, they were not expressing the NANOG transgene. 
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3.4 miRNA-mediated Knockdown of NANOG 
 
3.4.1 Generation of a Constitutive NANOG Expression Plasmid 
For simplicity, a constitutive NANOG expression plasmid was prepared as a 
replacement for the inducible PB-TRE-NANOG plasmid. The NANOG fragment 
that was initially ligated into the PB-TRE plasmid, was ligated into a linearized 
CMV plasmid derived from pEGFP-N1 (Fig. 15A) and used to transform bacteria 
which were cultured overnight under kanamycin selection. Transformation was 
successful with hundreds of colonies present on the positive plate, of which, four 
were randomly selected to be grown up for a miniprep. A SalI/NotI restriction 
digest on the four minipreps revealed that all four clones had correctly ligated the 
NANOG expression plasmid giving the expected pattern of bands; one at 3.9 kb 
(CMV backbone) and one at 900 bp (NANOG fragment) (Fig. 15B). 
 
 
 
Fig. 15. SalI/NotI restriction digestion of the CMV-NANOG plasmid. A. Schematic 
representation of the CMV-NANOG plasmid showing the approximate position of the 
SalI and NotI restriction enzyme cut sites. B. Gel electropherogram of a SalI/NotI 
restriction digestion showing that all four bacterial CMV-NANOG clones had correctly 
ligated the NANOG plasmid. 
 
To validate the CMV-NANOG plasmid for NANOG expression, one of the 
minipreps (miniprep 38) was transfected using the Lipofectamine® LTX protocol 
into a 3 cm dish of passage 5 BEFs. The following day, glass coverslips were 
removed from the culture dish and ICC was performed using the eBioscience 
mouse monoclonal NANOG antibody and the red Alexafluor® donkey anti-
mouse secondary antibody (Fig. 16).  The NANOG stain was specific and nuclear 
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localised. A non-transfected control remained negative for NANOG expression as 
did the negative ICC control. Transfection efficiency, based on the number of 
NANOG positive cells, was estimated to be around 35%. The validated miniprep 
was then used for all subsequent transfection experiments. 
 
 
 
Fig. 16. ICC staining for NANOG after transient transfection with the CMV-
NANOG plasmid. Black and white images were captured using the Olympus fluorescent 
microscope and were pseudo-coloured using ImageJ. Scale bar = 50 µm  
 
3.4.2 Cotransfection of BEFs with CMV-NANOG and NANOG miRNAs 
To determine the knockdown potential of the NANOG miRNAs, a cotransfection 
approach was undertaken whereby each miRNA was cotransfected into BEFs 
along with the NANOG expression plasmid, CMV-NANOG. Two days prior to 
transfection, passage five BEFs were thawed and seeded on 12-well plates 
containing round glass coverslips. On the day of transfection, cells were about 
80% confluent. The Lipofectamine® LTX protocol was used to cotransfect the 
CMV-NANOG plasmid with the miRNA plasmids at a 1:1 molar ratio. To 
determine efficiency and specificity of knockdown, the negative miRNA plasmid 
and the pMAX plasmid, respectively, were cotransfected with CMV-NANOG. A 
non-transfected control was also included. Each transfection experiment was 
performed in triplicate.  
 
Cells were visualised on the EVOS fluorescent microscope 24 hours after 
transfection. Transfection efficiencies, based on the number of GFP positive cells, 
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varied between the miRNA plasmids and were around 15 – 30%. Subsequently, 
coverslips were removed from each treatment well and ICC was performed using 
the eBioscience mouse monoclonal NANOG antibody and the red Alexafluor® 
donkey anti-mouse IgG secondary antibody (Fig. 17). As expected, not every cells 
which was took in the miRNA plasmid also took in the CMV-NANOG plasmid. 
On the negative miRNA control coverslips, an average of 40% of GFP positive 
cells were also positive for NANOG. To quantify NANOG knockdown, ten 
photos were taken from random fields of view for each coverslip. The number of 
GFP positive cells that were also positive for NANOG was then counted and 
divided by the total number of GFP positive cells. Proportions for each NANOG 
miRNA coverslip were normalised on the negative miRNA control proportion to 
account for the fact that not all cells would have taken in both plasmids.  
 
 
 
Fig. 17. ICC staining for NANOG after transient cotransfection of BEFs with CMV-
NANOG and NANOG miRNAs. White arrows indicate NANOG positive cells which 
are also positive for GFP. Black and white images were captured on the Olympus 
fluorescent microscope and were pseudo-coloured on ImageJ. Scale bar = 50 µm. 
 
The knockdown efficiencies for each miRNA were then determined which 
revealed all three NANOG miRNAs had a significant knockdown effect on 
bovine NANOG (Fig. 18). On average, miRNA 3 had the highest knockdown 
efficiency of 89.1% (P = 0.0007), followed by miRNA 2 with an 87.3% 
knockdown (P = 0.0029), and miRNA 1 with an 80.1% knockdown (P = 0.0014). 
Although significantly different from the negative miRNA control, the three 
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miRNAs were not significantly different from each other suggesting any of the 
three could be used for targeting endogenous NANOG in bovine embryos. The 
knockdown effect exhibited by the NANOG miRNAs was also found to be 
specific as the negative miRNA control exhibited no reduction in NANOG 
expression when compared to the pMAX transfected control (data not shown). 
 
 
 
Fig. 18. Percentage of NANOG knockdown in BEFs transiently cotransfected with 
CMV-NANOG and NANOG miRNAs. Knockdown percentage of the NANOG 
miRNAs is expressed relative to the negative miRNA control. Error bars based on SEM 
for biological replicates (n = 3), *P < 0.05 
 
The remaining cells from the transient cotransfection experiments were harvested 
for RNA extraction, followed by cDNA synthesis. The expression of NANOG and 
GFP was then investigated by qPCR. To account for differences in transfection 
efficiencies, NANOG expression levels were normalised on GFP expression. 
Compared to the negative miRNA control, NANOG expression levels appeared 
slightly reduced in the NANOG miRNA treated samples but these reductions 
were not found to be significant (miRNA 1, P = 0.18; miRNA 2, P = 0.32; 
miRNA 3, P = 0.45) (Fig. 19). 
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Fig. 19. Relative NANOG expression in BEFs transiently cotransfected with CMV-
NANOG and NANOG miRNAs. NANOG expression normalised against GFP 
expression. Neg miRNA = Negative miRNA. Error bars based on the SEM for biological 
replicates (n = 3). 
 
3.5 miRNA-mediated Knockdown of MBD3 
 
3.5.1 Transient Knockdown in BEFs 
A transient (24 h) MBD3 knockdown experiment was performed in BEFs to 
obtain a quick estimation of which miRNA plasmid had the most potent 
knockdown potential. Each MBD3 miRNA plasmid, as well as the negative 
miRNA control plasmid were individually transfected into 1 x 106 BEF cells via 
NeonTM electroporation. After 24 hours, cells were visualised on the EVOS 
fluorescent microscope. Phase contrast images were taken to document cell 
density while GFP images were captured in the green fluorescent channel to 
estimate the transfection efficiency. Cell viability was found to be severely 
compromised by the transfection protocol with approximately 50% cell death. 
Transfection efficiency, based on the number of GFP positive cells, was also 
lower than expected at approximately 20%. The experiment was repeated twice 
more in BEFs using the Lipofectamine® LTX protocol which did not compromise 
cell viability. Cells were transfected in a 24-well format. Transfection efficiencies 
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were similar to the initial NeonTM electroporation transfection and ranged between 
30 – 35%.   
 
Knockdown potential was determined by ICC and qPCR analysis. Surprisingly, 
no difference in MBD3 protein expression was observed between cells transfected 
with either one of the MBD3 miRNA plasmids or the negative miRNA control 
plasmid (Fig. 20). The MBD3 stain was found to be almost entirely nuclear 
specific. Focusing specifically on cells with the highest GFP intensity (i.e. should 
be highly expressing the MBD3 miRNA), there was no difference in intensity of 
MBD3 compared to cells which were not GFP positive (i.e. were not expressing 
the MBD3 miRNA plasmid).  
 
 
 
Fig. 20. ICC staining for MBD3 after transient transfection of BEFs with MBD3 
miRNAs. ICC staining for MBD3 focusing on cells which have a high GFP expression. 
White arrows identify the oddly shaped nuclei of the GFP expressing cells. Black and 
white images were captured on the Olympus fluorescent microscope and were pseudo-
coloured using ImageJ.  
 
Interestingly, cells which were GFP positive exhibited oddly shaped nuclei. This 
unusual artefact was observed not only in the MBD3 miRNA transfected cells but 
also in cells transfected with the negative miRNA control. This would suggest that 
an abnormally shaped nucleus was related in some part to the BLOCK-iTTM 
miRNA expression plasmid rather than a specific effect of MBD3 knockdown. In 
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agreement with the protein data, no significant MBD3 knockdown was observed 
on the mRNA level (Fig. 21). 
 
 
 
Fig. 21. Relative MBD3 expression in BEFs transiently transfected with MBD3 
miRNAs. MBD3 expression normalised against GFP expression. Neg miRNA = 
Negative miRNA. Error bars based on SEM for biological replicates (n = 3). 
 
3.5.2 MBD3 Half-Life Experiment 
In an attempt to explain why no miRNA-mediated knockdown of MBD3 was 
observed after 24 hours, an experiment was designed to determine the protein 
half-life of MBD3. Approximately 5 x 105 passage 9 BEFs were thawed and 
seeded onto a 6 cm culture dish containing 12 round glass coverslips. The 
following day, cells were treated with 10 µg/ml cycloheximide to inhibit protein 
translation. Two coverslip were removed just prior to act as the negative ICC 
control and the 0 hour (h) protein control (t0). The other coverslips were then 
removed at the following time points: 6 h, 12 h, 24 h, 36 h, 48 h, 63 h, 72 h, 88 h, 
96 h, 112 h. To maintain the level of cycloheximide, base media and 
cycloheximide were replaced at the 63h time point. 
 
Once removed, coverslips were fixed with 4% PFA for 15 minutes, washed three 
times with PBS and then stored at 4⁰C. After all coverslips had been fixed, the 
presence of MBD3 was assessed by ICC (Fig. 22). Expression of the MBD3 
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protein could still be detected even after 112 h of inhibiting protein synthesis. 
MBD3 expression was consistently nuclear in localisation and its staining 
intensity was reduced the longer protein translation was inhibited.  
 
 
 
Fig. 22.  ICC staining for MBD3 on cells exposed to cycloheximide for 0 – 112 hours. 
Black and white images were captured using the Olympus fluorescent microscope and 
were pseudo-coloured using ImageJ. Scale bar = 50 µm  
 
 
To determine the half-life of the protein, ICC images were opened on ImageJ and 
the area and pixel-intensity (PI) of ten nuclei from each time point were measured. 
The PI measurements were then subtracted by the average of three background PI 
measurements taken from random background positions. The adjusted PI 
measurements were then normalised against their respective area measurement. 
For each time point, the ten normalised PI measurements were averaged and then 
expressed as a fold change over the t0 measurement (Fig. 23). The linear 
regression estimated the half-life of MBD3 to be approximately 48 hours. 
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Fig. 23. MBD3 half-life estimate. Nuclei from cells treated with the protein translation 
inhibitor cycloheximide for 0 to 96 h were quantified for MBD3 expression by measuring 
their pixel-intensity (PI) from ICC images on ImageJ. PI values for 24, 48, 72, and 96 h 
time points were normalised on nuclei area are expressed as a fold-change over the 0 h 
time point (to). A linear regression trendline has been plotted and the equation and 
correlation coefficient (R2) are displayed. Error bars represent SEM for biological 
replicates (N=10). 
 
3.6 Stable Knockdown of NANOG and MBD3 
 
3.6.1 Blasticidin Kill Experiment 
The practicality of the BLOCK-iTTM miRNA expression system for embryo 
research relies on its ability to generate stable knockdown cell lines which can 
then be used for SCNT. To select for stable transfectants that had integrated the 
miRNA plasmid into the genome, the optimal concentration of blasticidin for 
selection in bovine cells had to first be determined. 
 
A previous experiment had already shown that 5 µg/ml of blasticidin was 
sufficient to kill 100% of BEFs within a week (data not shown). To determine the 
optimal concentration for the EF5-TET bovine line, 1x106 EF5-TET cells were 
thawed and split across a 6-well plate. The following day, an image was captured 
on the EVOS fluorescent microscope to document cell density. Thereafter, cells 
were treated with either 0, 2, 4, 6, 8, or 10 µg/ml of blasticidin. Selection media 
was refreshed every 48 hours and photos were captured every day to qualitatively 
document the rate of cell death (Fig. 24)  
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Fig. 24. The effect of various concentrations of blasticidin on EF5-TET cells. Phase 
contrast images were captured daily on the EVOS fluorescent microscope for up to 9 days. 
Blasticidin selection media was added on Day 0 (D0) and was refreshed every 48 hours. 
Scale bar = 400 µm 
 
After 48 hours, cells treated with either 6, 8, or 10 µg/ml of blasticidin looked 
stressed and had begun detaching from the adherent culture plate. By the sixth day 
of selection, all of these cells had died. By contrast, cell death took slightly longer 
in the 4 µg/ml blasticidin treatment well, taking 10 days to achieve complete cell 
death. A blasticidin concentration of 2 µg/ml resulted in a minimal amount of cell 
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death, with cells growing to confluence within 48 hours. Likewise, cells not 
treated with blasticidin remained viable and continued to grow until they reached 
confluence. 
 
3.6.2 Short-Term Blasticidin Selection 
The first attempt to generate stable knockdown transfectants was carried out on 
BEFs. Approximately 2 x 106 passage 5 BEFs were thawed and seeded onto 10 
wells of a 12-well plate. Once cells had reached 80% confluence, they were 
transfected using the Lipofectamine® LTX protocol. The first six wells were 
transfected with either one of the NANOG or MBD3 miRNA plasmids, while the 
remaining four wells served as controls; one was transfected with the negative 
miRNA control plasmid, another with the positive lacZ miRNA plasmid, one with 
the GFP plasmid, pMAX, and one well was left as a non-transfected control. 
 
Transfection efficiencies after 24 hours varied between the different miRNA 
plasmids but were estimated to be between 20 – 30%. The same day, cells were 
passaged and split 1 to 6 onto fresh culture dishes ensuring cells would be spread 
thin for selection. Blasticidin selection was initiated 48 hours post-transfection to 
enable cells which had stably integrated the miRNA plasmid to be selected. 
Blasticidin was added to base media at a concentration of 10 µg/ml. Selection 
media was refreshed every 48 hours and cells were checked routinely for colony 
formation. 
  
Unexpectedly, BEFs transfected with the miRNA plasmids continued to grow 
under selection suggesting these cells were expressing the blasticidin resistance 
gene encoded on the BLOCK-iTTM plasmid. However, these cells were not 
positive for GFP expression. Moreover, the few cells that were GFP positive 
appeared not to have divided as no GFP expressing doublets were observed. By 
the eighth day of selection, these non-fluorescent cells had reached complete 
confluence. By contrast, the non-transfected cells and cells transfected with 
pMAX had all died within a few days of blasticidin selection. 
 
As selection of clonal lines seemed no longer possible, the blasticidin resistant 
cells were harvested for RNA extraction followed by cDNA synthesis. To 
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determine whether the blasticidin resistant cells from the miRNA transfected 
dishes were also expressing the miRNA plasmid, despite not being GFP positive, 
a qPCR assay was performed. Because the miRNA could not be detected directly, 
the cDNA samples were analysed for MBD3 and GFP expression. The qPCR 
assay revealed that there was no significant difference in MBD3 expression levels 
between cells transfected with the negative miRNA control plasmid and any of the 
MBD3 miRNA transfected cells (Fig. 25). As expected, GFP expression was not 
detectable in any of the treatment cells. 
 
 
 
Fig. 25. Relative MBD3 expression in BEFs stably transfected with MBD3 miRNAs. 
BEFs were harvested for RNA extraction and cDNA synthesis after reaching confluence 
on day 8 of blasticidin selection. MBD3 expression normalised against the housekeeping 
gene 18S. Neg miRNA = Negative miRNA. Error bars based on the SEM for technical 
triplicates. 
 
Two more attempts were made to generate stable knockdown cell lines this time 
using a different bovine cell line, EF5-TET. The miRNA plasmids were 
transfected into EF5-TET cells firstly using the Lipofectamine® LTX protocol 
and, on a separate attempt, using the NeonTM electroporation protocol. Included 
each time was a pMAX transfection control and a non-transfected EF5-TET 
control. Consistent with the previous BEF experiment, all control cells died within 
a few days of blasticidin selection while the miRNA transfected cells grew to 
complete confluence by the eighth day of selection. Once again, the majority of 
these cells were not positive for GFP expression. 
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3.6.3 Long-Term Blasticidin Selection 
Out of curiosity, a final stable knockdown experiment was conducted with the 
intention of applying blasticidin selection for a longer period of time. 
Approximately, 2 x 106 passage 6 BEFs were seeded across 10 wells of a 12-well 
plate and transfected as described in the first BEF experiment using 
Lipofectamine® LTX. The following day, cells were visualised on the EVOS 
fluorescent microscope. Phase contrast images revealed that the cells had reached 
100% confluence. Transfection efficiency was estimated to be about 30 - 40%.  
Each treatment well was then passaged and 2 x 105 cells were seeded onto a 10 
cm tissue culture dish. 
 
Blasticidin selection was initiated 48 hours post-transfection at a concentration of 
10 µg/ml (Fig. 26A). Selection media was refreshed every 48 hours for up to three 
weeks. Images were captured on the EVOS fluorescent microscope every two 
days to document cell density and GFP expression. After four days in selection, 
the pMAX transfected cells and the non-transfected cells had all died. By contrast, 
cells in the miRNA transfected dishes had minimal amounts of cell death with the 
population of non-fluorescent cells continuing to divide. By the eighth day of 
blasticidin selection, the GFP positive cells in the miRNA transfected dishes had 
still not proliferated and had become completely overgrown by non-fluorescent 
blasticidin resistant cells (Fig. 26B). 
 
Approximately three days after reaching 100% confluence, the non-fluorescent 
population of cells started to die. As the non-fluorescent cells detached from the 
culture dish, the GFP positive cells suddenly begun to proliferate. By the 20th day 
of blasticidin selection, distinct cell colonies were apparent, of which 70% were 
positive for GFP expression (Fig. 26C). Colonies were transferred the following 
day to a 48-well plate for expansion as well as onto an 8-well chamber for 
characterisation. A total of 22 cell colonies were successfully transferred; eight for 
NANOG miRNA 1, three for NANOG miRNA 2, six for NANOG miRNA 3, and 
five for MBD3 miRNA 4. Due to bacterial contamination of the lacZ miRNA, 
negative miRNA, and MBD3 miRNA 5 and miRNA 6 plates earlier on in 
selection, no cell colonies were obtained for these plasmids. After transfer to 
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individual culture, the cell clones failed to proliferate, with all clones entering into 
a state of cellular senescence. 
 
 
Fig. 26. Blasticidin selection in BEFs transfected with either NANOG, MBD3, or 
control miRNA plasmids. Images were captured on the EVOS fluorescent microscope. 
Scale bar = 400 µm. A. Initial seeding density and GFP expression at the initiation of 
blasticidin selection (day 0), 48 hours post-transfection. B. Seeding density and GFP 
expression on day 8 of blasticidin selection. C. GFP positive clonal populations after 20 
days of blasticidin selection. 
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3.7 BLOCK-iTTM Positive Control Experiment: LacZ Knockdown 
The lacZ miRNA plasmid supplied by the BLOCK-ITTM miRNA expression kit 
was used as a positive control for RNAi mediated knockdown. In preparation for 
the positive control experiment, the bovine commercial cell line CCL44 was 
seeded onto three wells of a 6-well tissue culture plate. Each well contained three 
coverslips. Once the cells had grown to about 70% confluence, they were 
transfected according to the Lipofectamine® LTX protocol. The first two wells 
were cotransfected with the lacZ reporter plasmid and either the lacZ miRNA or 
the negative miRNA control plasmid at a 1 to 6 molar ratio. The third well served 
as the non-transfected control. Coverslips were removed from culture dishes the 
following day for X-Gal staining. 
 
Cells positive for β-galactosidase were visualised under bright field while total 
cell nuclei were visualised under the blue immunofluorescence channel using the 
Olympus fluorescent microscope. Knockdown quantification was performed by 
calculating the proportion of cells that were blue and thus positive for β-
galactosidase. About 8% of cells cotransfected with the lacZ reporter and the 
negative miRNA plasmid were positive for β-galactosidase, indicative of a low 
transfection efficiency. By contrast, no β-galactosidase positive cells were present 
in cells transfected with the lacZ reporter and lacZ miRNA plasmid suggesting a 
complete knockdown. As expected, the non-transfected control cells were also 
negative for β-galactosidase expression. 
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The primary aim of this research project was to determine the feasibility of using 
a miRNA-based RNAi approach to knockdown NANOG and MBD3 in a bovine 
model. Using the BLOCK-iTTM miRNA expression system, we constructed three 
miRNA constructs designed to target different regions of either the NANOG or 
MBD3 transcript. In vitro screening of the miRNAs to determine their potency 
revealed that all three NANOG miRNAs were capable of significantly knocking 
down NANOG expression by as much as 89%. The knockdown potential of the 
MBD3 miRNAs is still yet to be determined due to the longevity of the MBD3 
protein which complicates transient miRNA expression analysis. Various attempts 
were made to derive stable NANOG or MBD3 knockdown cell lines. However, 
stable transfectants that were GFP positive were slow to proliferate and failed to 
expand after transfer to individual culture. This meant that no stable knockdown 
lines were established that could be used for SCNT. 
 
Our results are particularly disappointing given that the BLOCK-iTTM miRNA 
expression system has previously been demonstrated to be an effective tool for 
silencing genes in livestock. In 2012, a separate group within our research 
organisation, AgResearch, used this miRNA system to successfully target and 
silence the major milk allergen, β-lactoglobulin (BLG) in cattle (Jabed et al., 
2012). An in vitro screening system was first established by cotransfecting COS-7 
cells with a bovine BLG plasmid and one of ten miRNA expression plasmids 
designed using RNAi designer. To account for differences in transfection 
efficiency, the expression of BLG was normalised against the expression of GFP 
encoded on the miRNA plasmid. BLG expression from cells cotransfected with 
bovine BLG and a scrambled miRNA control was used for baseline comparisons 
to determine the knockdown efficiency of each BLG-specific miRNA plasmid. Of 
the 10 miRNAs tested, eight showed BLG knockdown efficiencies greater than 
70%, with the most efficient miRNA achieving a knockdown of 97%. To 
determine the efficiency of miRNA-mediated BLG knockdown in vivo, the group 
carried out SCNT cloning using a bovine fetal fibroblast line engineered to 
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express the most efficient BLG targeting miRNA.  Of the 57 cloned embryos 
transferred into recipient cows, one resulted in the birth of a live female calf. After 
hormonally inducing her into lactation at 7 months of age, the milk of the 
transgenic calf was analysed by Western blot for BLG protein expression. With 
no detectable levels of BLG, and a higher overall level of casein proteins, the 
group concluded that targeted miRNA expression is an effective strategy for 
modifying milk composition and other important livestock traits. 
 
The BLOCK-iTTM miRNA expression system has also just recently been used to 
knockdown the skeletal muscle growth factor, myostatin in caprine fetal 
fibroblasts (CFFs) (Zhong et al., 2014). Natural mutations in the myostatin gene 
often result in a double muscling phenotype, a desirable trait for the agricultural 
industry (Bellinge et al., 2005). A previous knockdown attempt in cattle using 
integrating small hairpin RNA (shRNA) plasmids resulted in only slightly reduced 
myostatin levels in one of five transgenic calves (Tessanne et al., 2012). In an 
attempt to improve the efficiency of RNAi-mediated myostatin knockdown, a 
separate research team instead selected the BLOCK-iTTM miRNA expression 
system to reduce myostatin levels in a caprine (goat) model (Zhong et al., 2014). 
Preliminary in vitro results have shown that the targeting miRNA plasmids can 
achieve transient knockdown efficiencies between 71-84% in CFFs when 
compared to non-transfected controls. However, their negative miRNA control 
plasmid also achieved a similar transient knockdown. This suggests that the 
reduction in myostatin was not a miRNA-specific response, but rather due to an 
elicitation of an immune response within the CFF as characterised by an increase 
in interferon gene expression. Stable knockdown attempts, resulted in a lower 
immune response but knockdown efficiency of myostatin was reduced to 31% 
compared to non-transfected controls. Importantly, neither Jabed et al. nor Zhong 
et al. reported any issues generating stable knockdown cell lines suggesting that 
the slow-proliferative nature of GFP positive cells is a phenomenon unique to our 
system. 
 
4.1 Objective One: Design and Generation of the miRNA Constructs 
The design of a miRNA is fundamental to its specificity and knockdown potential. 
Unfortunately, even when using established RNAi design software, there is no 
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guarantee that a particular miRNA will specifically and efficiently knockdown its 
respective mRNA target. For these reasons, researchers often design multiple 
miRNA molecules to target various different regions of the same mRNA 
transcript. In vitro screening is then applied to identify which miRNA has the 
most potent and specific knockdown potential before moving on to the in vivo 
model.  
 
To knockdown the expression of bovine NANOG and MBD3, three miRNAs 
specific for each gene transcript were designed using Invitrogen’s RNAi designer. 
During the design process, the target binding region as well as the GC content 
were taken into consideration. All three of the miRNAs for each gene were 
designed to target the ORF as opposed to the 3’ or 5’ UTRs. This decision to 
target the ORF was based on the assumption that UTR-binding proteins could 
potentially interfere with RISC binding and thus negatively impair miRNA 
activity. Furthermore, it was also assumed that UTR targeting might result in 
more off-target effects as UTR sequences can be similar across different mRNA 
transcripts (Jabed et al., 2012). 
 
Based on Invitrogen’s recommendation, NANOG- and MBD3-specific miRNAs 
were designed to have a GC content between 35 – 55%. Too high of a GC content 
is thought to negatively impair RNAi activity by slowing down helicase’s ability 
to unwind the double-stranded miRNA duplexes during RISC assembly (Chan et 
al., 2009). In addition, due to their potential to hyperstack into agglomerates and 
thus inhibit miRNA-mediated silencing, strings of more than three Gs or Cs in a 
row were also avoided (Kumar & Clarke, 2007). 
 
Another important criteria of miRNA design is specificity. To avoid any off-target 
effects, the designed miRNAs were screened against the entire bovine genome 
using BLAST which confirmed their specificity for either NANOG or MBD3 with 
no homology to any additional gene transcripts. Another cause of off-target 
effects, as mentioned earlier in the myostatin knockdown study, is the unwanted 
elicitation of an immune response caused by activation of Toll-like receptors. The 
triggering of an immune reaction in response to the miRNA construct or its 
delivery vehicle can result in global degradation of total mRNA as well as protein 
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translation inhibition (Singh et al., 2011). To minimise the elicitation of an 
immune response, we opted to use Invitrogen’s BLOCK-iTTM expression system 
which allows for transfectional entry into mammalian cells. By comparison, viral 
transduction of the miRNA construct is more likely to trigger an immune reaction 
and thus lead to more off-target effects complicating knockdown analyses (Azzam 
& Dom, 2004). Conscious of the immune response observed by Zhang et al. with 
their myostatin miRNAs, we made sure we always included a non-transfected 
control to compare to cells transfected with the negative miRNA plasmid. In 
doing so, we were able to verify that protein knockdown was not due to any non-
specific effects. 
 
4.2 Objective Two: Evaluation of miRNA Knockdown Potential 
After construction of the various miRNA plasmids targeting either the NANOG or 
MBD3 transcript, the next objective was to identify which one had the most potent 
and specific knockdown potential.  
 
4.2.1 NANOG Knockdown 
Expression of NANOG is confined to only a subset of cells within the ICM of the 
early embryo. Testing miRNA-mediated knockdown using IVP embryos or their 
isolated ICM cultures would have been very labour intensive and costly as the 
number of NANOG expressing cells within these systems are limited. Therefore, 
a large number of biological samples would have been required. Furthermore, the 
most effective method of delivering the BLOCK-iTTM miRNA plasmids would 
have been to microinject them into one-cell embryos. However, NANOG is not 
expressed until day 7 in bovine blastocysts, at which point the injected miRNAs 
would have degraded. Therefore, to develop a robust screening assay for 
validating the activity of the NANOG miRNAs, a NANOG expressing cell line 
was required.  
 
In contrast to the cotransfection approach used by Jabed et al. who transiently 
transfected in a BLG expression plasmid alongside one of their BLG-specific 
miRNA plasmids, we decided it would be ‘cleaner’ to first generate a stably 
transfected NANOG cell line. Our intention was to use the NANOG expressing 
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cell line to evaluate the activity of the three NANOG miRNAs ensuring an equal 
‘playing field’ for knockdown.  
 
Previously our laboratory had successfully generated a bovine NANOG 
overexpressing fibroblast line that was doxycycline-inducible. This cell line, 
EOG-TET-NANOG, was initially selected for screening the NANOG miRNAs. 
However, we discovered that the NANOG transgene within this line had been 
extensively codon optimised during synthesis. Codon optimisation is typically 
performed when designing transgenes for protein production as it allows for 
uncommon and inefficiently translated codons to be replaced by the most efficient 
codon. In this way, protein translation can be significantly enhanced (Burgess-
Brown et al., 2008). Despite the amino acid sequence remaining unchanged, the 
nucleotide sequence can be significantly altered, as was the case for the codon 
optimised NANOG transgene within EOG-TET-NANOG. As the NANOG 
miRNAs were designed against the endogenous NANOG transcript, we presumed 
and later confirmed that they were unable to target the codon-optimised NANOG 
transgene. Therefore, a second NANOG expressing cell line had to be generated 
for screening purposes. 
  
To circumvent the issues of cellular stress and poor cell growth that occur from 
protein overexpression, we decided to use the highly efficient doxycycline-
inducible piggyBac expression system (Li et al., 2013). This was the first time, to 
our knowledge, that this inducible piggyBac system has been used in a bovine 
model. However, piggyBac plasmids containing doxycycline-inducible transgenes 
have been shown to be an efficient strategy for modifying gene expression in 
various other animal cell types, including mice (Cardiñanos & Bradly, 2007, 
Tsukiyama et al., 2011), human (Saridey et al., 2009, Wang et al., 2011), and 
chicken (Glover et al., 2013). 
 
The EF5-TET bovine embryonic fibroblast cell line was initially selected for 
transfection of the PB-TRE-NANOG plasmid because it had already been 
engineered to express the rtTA required for activation of the TRE promoter. The 
PBase plasmid, pCyL43, was cotransfected with the PB-TRE-NANOG into low 
passage EF5-TET cells at a 1 to 5 molar ratio respectively. Too high of a 
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concentration of the PBase plasmid is known to be detrimental to transgenic 
delivery due to its ability to re-excise the already integrated transposon based 
transgenes from the host’s genome (Wang et al., 2008). In addition, the lingering 
of the PBase can also evoke an immune response, preventing efficient integration 
of the transgenes (Chakraborty et al., 2014). Previous piggyBac experiments using 
the EF5-TET line had revealed that a 1 to 5 molar ratio of transposase to 
transposon was optimal for efficient transgene delivery resulting in high 
integration rates eliminating the need to select for stable transfectants (Andria 
Green, personal communication, 2014).  
 
Unfortunately, we were unable to replicate such efficient integrative transfection 
results when using the PB-TRE-NANOG plasmid. Of the one million EF5-TET 
cells transfected, only 28 puromycin resistant cell clones were selected, and many 
of them did not continue to grow during expansion. During the NANOG 
validation experiments, we discovered that there was a disagreement between the 
protein and mRNA data. Of the seven clones that grew to the validation stage, six 
showed a significantly elevated expression of NANOG mRNA compared to a non-
transfected EF5-TET control. Four clones exhibited a high expression level of 
NANOG which was between 37 – 67 fold higher than the control, while the other 
three had only marginal differences in NANOG expression (between 1.5 – 5 fold). 
However, on the protein level, all seven clones were positive for NANOG with no 
detectable differences in ICC staining intensity between the clones.  
 
To characterise the NANOG clones, the ICC protein assay was selected as it 
allowed us to detect NANOG expression on the single cell level. However, 
quantification via ICC is difficult requiring numerous cell images to be assessed 
for pixel-intensity differences. Ideally, it would have been better to analyse 
NANOG expression by Western blot which would have made it easier to quantify 
and compare protein expression between the clones. Unfortunately, the 34 kDa 
NANOG protein is notoriously difficult to visualise on a Western blot as it 
fragments easily resulting in multiple bands. In our laboratory, previous Western 
blot attempts to stain for NANOG using eight different commercial antibodies and 
various protein lysates have been unsuccessful (Bjorn Oback, personal 
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communication, 2014). For these reasons, we had to rely on ICC data to validate 
protein expression. 
 
One big limitation for cell research in animals which do not yet have established 
ESC lines is cellular senescence. Normal somatic cells have a finite lifespan and 
will only divide a certain number of times before entering into cellular senescence 
– a metabolically active state where the cell can no longer proliferate. This 
division limit is more commonly referred to as a cell’s Hayflick limit (Hayflick & 
Moorhead, 1961). Hayflick limits vary between different cell types and for many 
primary bovine fibroblast lines, the Hayflick limits have yet to be accurately 
determined. Unfortunately, even though we initially transfected low passage EF5-
TETs, all seven of our NANOG expressing clones failed to proliferate after the 
validation experiments, with all entering into a state of cellular senescence.  
 
In an attempt to override the cellular senescent state, a transformation experiment 
was performed using the oncogene c-myc plasmid. The c-myc gene encodes a 
transcription factor that is known to play a prominent role in regulating cell cycle 
progression. Specifically, it has been found to upregulate various cyclin proteins 
and ribosomal components encouraging cell growth and proliferation (Henriksson 
& Luscher, 1996, Prall et al., 1998). In addition c-myc is capable of inducing the 
expression of telomerase reverse transcriptase (TERT), a catalytic subunit of the 
enzyme telomerase which maintains telomeric length, enabling cells to 
continually divide (Gil et al., 2005). Testament to its role in cell proliferation, 
many cancers have been found to harbour mutations in the c-myc gene resulting in 
its constitutive expression (Dhang, 1999). Taking advantage of these properties, 
numerous researchers have discovered that mammalian cells, including bovine 
cells, can be transformed into an immortalised state by simple transfection of a c-
myc transgene (Drissi et al., 2001, Gil et al., 2005, Bi et al., 2007). Importantly, c-
myc transfected cells have been shown to maintain a normal karyotype ensuring 
the properties of the cell are not significantly altered (Gil et al., 2005). However, 
once a cell has already entered into senescence, it is particularly difficult to 
transform due to the much lower transfection efficiency (Di Micco et al., 2006). 
This would explain why we did not detect any RFP signal following transfection 
of the RFP-containing C-MYC plasmid into the senescent NANOG cell clones. 
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By contrast, transfection of the non-senescent EF5-TET control cells was 
successful with a transfection efficiency of around 30%. This suggests that lipid-
based plasmid delivery is not an effective strategy for immortalising already 
senescent cells. An alternative approach to immortalise the NANOG clones is to 
use a lentivirus to deliver the C-MYC transgene as lentiviral vectors are capable of 
efficiently integrating into non-dividing cells (Naldini et al., 1996). A separate 
approach that does not require immortalisation, would be to try and rejuvenate the 
cell clones by using them as donor cells for SCNT cloning and then recovering the 
embryos at around D45 of embryonic development. Due to time constraints and 
the high risk of transgene silencing that accompanies SCNT, this approach was 
not pursued.  
 
To avoid issues with cellular senescence, we decided to transfect PB-TRE-
NANOG into an already immortalised cell line. The human cervical cancer cell 
line HeLa was selected because of its robust proliferation. However, the HeLa line 
did not already contain the rtTA transgene which meant a triple transfection of all 
three piggyBac plasmids was required. An electroporation-based transfection 
method was used due to its ability to achieve higher transfection efficiencies than 
lipid-based transfection approaches. Unfortunately, the lack of a fluorescent 
reporter plasmid meant that there was no way of initially assessing transfection 
efficiency. Instead, we had to rely on cells being puromycin resistant as a proxy 
for determining which cells had integrated both plasmids. As it turned out, this 
was not a reliable strategy as one HeLa clone spontaneously developed resistance 
to puromycin and was later confirmed to be negative for NANOG expression.  
 
Similar to the EF5-TET transfection, the integrative efficiency of the inducible 
piggyBac plasmids, PB-TRE-NANOG and PB-CAG-rtTA in HeLa cells was 
extremely low, despite the inclusion of the PBase plasmid. A total of four million 
cells were transfected with all three plasmids but no NANOG expressing cell 
clones were produced. This suggests that our inducible piggyBac expression 
system, which has previously been shown to be highly efficient, was not working 
as expected. Because the EF5-TET experiment had resulted in some positive 
NANOG clones, it suggested that perhaps the PB-CAG-rtTA plasmid was at fault. 
However, two other attempts substituting the PB-CAG-rtTA plasmid with a 
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commercial non-transposon containing rtTA plasmid, EF1α-Tet3G, also did not 
result in any NANOG positive HeLa clones (data not shown) and so ultimately 
the inducible piggyBac system was abandoned and its inefficiency remains 
unresolved.  
 
For simplicity, we then decided to return to the co-transfection approach used by 
Jabed et al., to determine the knockdown efficiencies of their BLG-specific 
miRNAs. A constitutive NANOG expression plasmid was prepared and was 
validated for NANOG expression by ICC following transient transfection into a 
BEF cell line. Because the half-life of the NANOG protein is two hours, transient 
(24 h) miRNA expression should result in a detectable knockdown effect. 
Therefore, transient knockdown experiments were performed by cotransfecting 
the CMV-NANOG plasmid alongside either one of the three NANOG-specific or 
control miRNA plasmids. ICC analysis was performed and knockdown potential 
was assessed by calculating the proportion of GFP positive cells that were also 
positive for NANOG. However, not every cell that took in the miRNA plasmid 
also took in the CMV-NANOG plasmid. To account for this, NANOG miRNA 
proportions were normalised against the proportions calculated from the negative 
miRNA control. Although not an ideal screening system, the protein knockdown 
assay revealed that all three NANOG miRNAs had significantly knockdown 
NANOG expression. Of the three miRNA plasmids, miRNA 3 was found to have 
the highest knockdown efficiency at 89.1%, closely followed by miRNA 2 on 
87.3% and then miRNA 1 with 80.1%. When the negative miRNA control was 
compared to the pMAX transfection control, no knockdown effect was observed 
suggesting that the NANOG knockdown exhibited by the NANOG miRNAs was 
a specific effect and not the result of an immune response. These results suggest 
that either one of the NANOG miRNA plasmids would be a good candidate for 
future in vivo experiments. 
 
On the mRNA level, there was no significant difference in NANOG expression 
between the various NANOG-specific and control miRNAs. This is not surprising 
given the high background nature that accompanies a transient cotransfection 
approach. To improve the sensitivity of the qPCR assay would require a 
significant increase in transfection efficiency. For the qPCR assay to be 
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informative, Invitrogen recommend transfection efficiencies upwards of 70% 
(Invitrogen Tech Support, personal communication, 2014). A number of factors 
are known to influence transfection efficiency including plasmid size and purity, 
plasmid form (linearised vs. circular), promoter choice and delivery vehicle 
(Colosimo et al., 2000). One method used to improve transfection efficiencies, 
which we did not pursue, is to subject transfected cells to a 10% glycerol (v/v) 
shock 20 minutes post-transfection for 3 minutes. Glycerol is known to disturb the 
endosome membrane and thus facilitate DNA release within the cell (Zauner et al., 
1997). By including the glycerol treatment, Jabed et al. were able to enhance the 
lipid-based transfection efficiency of their COS7 cells from 35 to 76% (Jabed et 
al., 2012). However, other researchers have reported no difference in transfection 
efficiency with additional glycerol treatment (Campeau et al., 2001).  
 
4.2.2 MBD3 Knockdown 
Unlike NANOG, MBD3 is ubiquitously expressed. Therefore, for assessing the 
knockdown potential of the MBD3-specific miRNAs, a standard BEF cell line 
was used. To quickly validate which miRNA had the most potent knockdown 
activity, a transient (24 h) transfection approach was undertaken. Achieving a 
high transfection efficiency is particularly important for transient knockdown 
assays which is why we initially performed the MBD3 miRNA transfection using 
the NeonTM electroporation protocol. However, cell viability was severely 
compromised by electroporation resulting in approximately 50% cell death and a 
low transfection efficiency of only 20%. By comparison, subsequent transient 
transfection attempts using Lipofectamine® LTX resulted in only minimal cell 
death with comparable transfection efficiencies.  
 
To observe protein knockdown, ICC staining for MBD3 was performed. No 
MBD3 knockdown was observed for any of the treatment groups even when 
focusing on the cells with the highest expression of GFP. As the GFP transcript is 
produced in cis with the pre-miRNA, these cells should have also been highly 
expressing the MBD3-specific miRNA and thus cells should have had reduced 
MBD3 expression. However, the intensity of the MBD3 stain was no different to 
the intensity of MBD3 in non-GFP positive cells.  
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We suspected that the reason why no MBD3 knockdown was observed on the 
protein level after transient transfection with MBD3-specific miRNAs was 
because MBD3 has a long protein half-life. If true, 24 hours of mRNA 
knockdown would not have been evident on the protein level as the existing 
MBD3 protein would not have been degraded within the time period. To support 
this hypothesis, a protein inhibition time course experiment was performed to 
estimate the half-life of MBD3. Cells were treated for between 0 - 112 hours with 
the fast-acting protein translation inhibitor, cycloheximide. ICC staining for 
MBD3 revealed that the protein was still present even after 112 hours of 
cycloheximide exposure. Quantification of MBD3 staining intensity was 
performed which revealed MBD3 has an approximate half-life of 48 hours. 
Because degradation of the BLOCK-iTTM plasmid within the cytoplasm also 
occurs within 48 hours, it meant that a transient transfection approach was not 
going to be a feasible option for reducing MBD3 protein levels in vitro.  
 
Given that the half-life of the MBD3 transcript is 8.5 hours, a knockdown effect 
should have been detectable on the mRNA level. However, similarly to the 
NANOG qPCR assay, no significant difference in MBD3 mRNA expression was 
detected between cells transfected with either one of the MBD3-specific miRNAs 
and the negative miRNA control even when normalised on GFP expression. 
Although not significant, the qPCR data do suggest that MBD3 expression is 
reduced in MBD3 miRNA transfected cells. If the transfection efficiency were to 
improve, background MBD3 expression from non-transfected cells could be 
reduced and a knockdown effect could be quantified more accurately. 
 
4.3 Objective Three: Generation of Stable Knockdown Bovine Cell Lines 
A separate objective of this project was to generate stable knockdown cell lines. 
The stable lines would then serve as donor cells for SCNT enabling knockdown 
embryos to be produced in vitro and the specific biological functions of bovine 
MBD3 and NANOG could thus be determined. 
 
The successful generation of stable knockdown clones using the BLOCK-iTTM 
miRNA expression kit has previously been demonstrated by other researchers, 
including a stable BLG knockdown within a bovine fetal fibroblast line (Jabed et 
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al., 2012). Selection of stable transfectants is made possible by the blasticidin 
resistance gene encoded on the miRNA expression plasmid and driven by the 
constitutively active EM7 promoter, a synthetic version of the T7 bacteriophage 
promoter. The nucleoside antibiotic blasticidin kills both prokaryotic and 
eukaryotic cells by inhibiting protein synthesis (Yamaguchi et al., 1965). 
Resistance to blasticidin is made possible by expression of the blasticidin S 
deaminase gene (bsd) (Kimura et al., 1994). Initially discovered in Aspergillus 
terreus, bsd converts blasticidin into a non-toxic deaminohydroxy derivative 
preventing protein synthesis inhibition (Izumi et al., 1991). 
 
Multiple attempts to generate stable knockdown clones were conducted. Two 
different bovine fibroblast cells lines were used to transfect in the NANOG, 
MBD3, or control miRNA plasmids using either the Lipofectamine® LTX or 
NeonTM electroporation protocols. Transfection rates varied between the different 
protocols but were typically between 20 – 60% based on the number of GFP 
expressing cells. Approximately 24 hours after transfection, cells were split 
harshly onto fresh culture dishes and blasticidin selection was initiated the 
following day at a concentration of 10 µg/ml. On all attempts, both the non-
transfected control cells and pMAX transfected cells all died within 2 to 4 days of 
blasticidin treatment suggesting they were not resistant. However, in the cells 
transfected with the miRNA expression plasmids, the GFP positive cells would 
not initially proliferate and would become overgrown by non-fluorescent 
blasticidin resistant cells. This occurred in all miRNA plasmids transfected 
including the negative and positive control plasmids supplied by the BLOCK-
iTTM miRNA expression kit. Subsequent qPCR analysis of the blasticidin resistant 
non-fluorescent cells from the MBD3 miRNA dishes suggested that they were not 
expressing the miRNA plasmid as there was no difference in MBD3 expression 
when compared to non-transfected controls. 
 
It seemed as though blasticidin resistance was occurring following transfection 
with the miRNA expression constructs but this did not correlate with GFP 
expression. One possible explanation for this occurrence could be that these cells 
had indeed integrated the plasmid but the GFP and pre-miRNA sequences had 
become methylated and consequently silenced within the genome while the 
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blasticidin resistance gene remained switched on. However, it is unlikely that this 
phenomenon would have occurred for every single miRNA construct on every 
single stable transfection attempt. 
 
Another possible explanation is promoter competition between the CMV 
promoter which drives expression of the GFP/miRNA transcript and the EM7 
promoter which drives expression of the blasticidin resistance gene. After 
integration into the genome, access to transcription factors and RNA polymerase 
could have become biased to one of the plasmid promoters, in this case, EM7. The 
lower expression of the GFP/miRNA transcript could have offered a selective 
growth advantage over cells which did express the GFP/miRNA transcript which 
would explain why these non-fluorescent cells were able to overgrow the GFP 
positive cell population.  
 
When cells reach complete confluence they either die or enter into a state of 
cellular quiescence (Gos et al., 2005). In this experiment, it appears the non-
fluorescent cells were unable to become quiescent at full confluence and instead 
started to die and lift off the culture dish. Without the presence of the non-
fluorescent cell population, the growth disadvantage of the GFP expressing cells 
was removed and these cells were then able to proliferate and form distinct cell 
colonies. However, after transfer to individual culture, the GFP positive clones all 
entered into a state of cellular senescence where they stopped proliferating. This 
failure to expand meant that no clonal knockdown cell lines were established and 
SCNT could not be performed to generate knockdown embryos. 
 
One possibility that was not explored, but could be advantageous moving forward, 
is to apply fluorescence activated cell sorting (FACS) to cells 24 hours post-
transfection. With the ability to sort heterogeneous cell populations according to 
their level of fluorescence, FACS would enable cells transfected with the miRNA 
expression plasmids that are GFP positive to be separated from non-GFP positive 
cells. Blasticidin selection could then be applied to only the GFP positive cells 
which may facilitate their proliferation as they would no longer have to wait for 
the non-fluorescent cell population to reach confluence and lift off. Previously, 
FACS coupled with selection media has proven to be an effective strategy for 
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generating high expression stable cell lines (Zhang et al., 2006). Using 
Lipofectamine®, Zhang et al. transfected Chinese hamster ovary (CHO) cells with 
a GFP expression plasmid followed by culture in selective growth media. By 
applying three rounds of FACS, the percentage of GFP positive cells increased 
eventually resulting in the establishment of high expressing cell lines. By 
comparison, non-FACS control cells experienced a rapid reduction in GFP 
positive cells and overall GFP induction was low.  
 
4.4 Conclusions and Future Recommendations 
In conclusion, we found that the BLOCK-iTTM miRNA expression system was 
capable of efficiently knocking down NANOG protein expression by as much as 
89%. Unfortunately, due to the longevity of the MBD3 protein, a knockdown 
effect was not apparent after transient miRNA expression. Frequent attempts were 
made to generate stable knockdown cell lines, a prerequisite for the generation of 
knockdown embryos by SCNT. Stably transfected GFP-miRNA expressing cells 
did not initially proliferate during blasticidin selection, becoming overgrown by 
non-fluorescent blasticidin resistant cells. Eventually, after three weeks of 
selection, we were able to isolate GFP-miRNA expressing clones. However, these 
clones failed to expand after transfer to individual culture. Future research efforts 
should be directed into understanding why the GFP positive cells do not initially 
proliferate under blasticidin selection after miRNA transfection. Further 
characterisation of the blasticidin resistant non-fluorescent cells would also be 
advantageous. For the BLOCK-iTTM miRNA expression system to be effectively 
applied in bovine embryos, these issues will need to be resolved. The inclusion of 
FACS to sort the GFP positive cells from the non-fluorescent cells immediately 
prior to blasticidin selection is one option that should be trialled before 
abandoning the BLOCK-iTTM miRNA expression system. 
 
However, should FACS also fail to generate stable knockdown cell lines, an 
emerging system which could be explored as an alternative to miRNA-mediated 
silencing is the clustered regulatory interspaced short palindromic repeat 
(CRISPR)/Cas9 genome editing system. Initially discovered in bacteria as a 
strategy to defend against invading phages, the CRISPR/Cas9 system has now 
been exploited by scientists to enable precise modification of specific sites within 
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the genome (Barrangou1 et al., 2007, Hsu et al., 2014).  Briefly, how this system 
works is that Cas9 is a nuclease capable of introducing double-strand breaks in 
DNA. Its specificity is determined by the inclusion of a guide RNA which in 
complex with Cas9, targets the nuclease to a complementary sequence within the 
genome. In an attempt to repair the double-strand break, the genome undergoes 
either non-homologous end joining or homology-directed repair which often lead 
to insertions or deletions within the sequence (Sander & Joung, 2014). In this way, 
gene knockout or knock-in phenotypes can be generated. Just recently, the 
CRISPR/Cas9 system was successfully used to specifically integrate a GFP 
transgene cassette into intron 1 of the NANOG gene locus in bovine iPSCs and 
embryos (Heo et al., 2015).  
 
With rapid progress in the construction of large guide RNA libraries, it will soon 
be possible to design guide RNAs to target virtually any gene within an organism 
(Sander & Joung, 2014). Because of its simplicity, high efficiency, and versatility, 
the CRISPR/Cas9 system is set to revolutionise transgenic research and would be 
an ideal alternative system for investigating the biological functions of bovine 
NANOG and MBD3, as it can be applied directly to embryos circumventing the 
need to first create a stable cell line. Guide RNAs could be microinjected into 
bovine embryos at the one-cell stage. However, not all of these embryos will be 
successfully mutated by the CRISPR/Cas9 system. Therefore, an embryo 
screening assay would have to be developed to allow embryos with a biallelic 
knockout to be selected for. Once a knockout embryo is confirmed, the biological 
function of bovine NANOG and MBD3 could then be determined. Overall, this 
research will help to improve our current understanding of bovine pluripotency 
specification which will likely assist in the ultimate goal of establishing authentic 
livestock-derived ESCs. 
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Appendix I. Plasmids 
 
Table I. Commercial plasmids 
 
Plasmid Source 
BLOCK-iTTM polII miR RNAi Plasmids  
 pcDNATM6.2-GW/EmGFP-miR Invitrogen (USA) 
 pcDNATM6.2-GW/EmGFP-miR-neg control Invitrogen (USA) 
 pcDNATM1.2/V5-GW/lacZ control Invitrogen (USA) 
PB-CAG-rtTA Wellcome Trust Sanger Institute (UK) 
PB-TET-MKOS Addgene (UK) 
pCyL43 Wellcome Trust Sanger Institute (UK) 
pEGFP-N1 Clontech Laboratories Inc. (USA) 
pEF1α-Tet3G Clontech Laboratories Inc. (USA) 
pMAX Lonza (Switzerland) 
pTRE3G-mCherry Clontech Laboratories Inc. (USA) 
TOPO-TA Invitrogen (USA) 
 
Table II. Plasmids derived from commercial plasmids 
 
Plasmid Derived from 
CMV-NANOG pEGFP-N1  
lacZ miRNA pcDNATM6.2-GW/EmGFP-miR 
NANOG miRNA 1 pcDNATM6.2-GW/EmGFP-miR 
NANOG miRNA 2 pcDNATM6.2-GW/EmGFP-miR 
NANOG miRNA 3 pcDNATM6.2-GW/EmGFP-miR 
MBD3 miRNA 4 pcDNATM6.2-GW/EmGFP-miR 
MBD3 miRNA 5 pcDNATM6.2-GW/EmGFP-miR 
MBD3 miRNA 6 pcDNATM6.2-GW/EmGFP-miR 
PB-TRE-NANOG PB-TET-MKOS 
pC-MYC pTRE3G-mCherry 
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Fig. I. Plasmid Map of PB-TRE-NANOG 
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Fig. II. Plasmid Map of CMV-NANOG. 
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Appendix II. Oligonucleotide Sequences 
 
 
Table III. MicroRNA oligonucleotides designed using RNAi designer (Invitrogen) and 
ordered from IDT except for the lacZ miRNA which was supplied with the Block-ITTM 
miRNA expression kit 
 
 
miRNA Target 
region 
Start 
site 
Sequence 5’ to 3’ 
NANOG 
miRNA1 
ORF 236 Top:TGCTGCATGGGTGAAGATTCCCTAGAGTTTTGGCC
ACTGACTGACTCTAGGGACTTCACCCATG 
 
Bottom:CCTGCATGGGTGAAGTCCCTAGAGTCAGTCAGT
GGCCAAAACTCTAGGGAATCTTCACCCATGC 
 
NANOG 
miRNA2 
ORF 264 Top:TGCTGTTTGCAAGGACACGTAACTTTGTTTTGGCC
ACTGACTGACAAAGTTACGTCCTTGCAAA 
 
Bottom:CCTGTTTGCAAGGACGTAACTTTGTCAGTCAGT
GGCCAAAACAAAGTTACGTGTCCTTGCAAAC 
 
NANOG 
miRNA3 
ORF 275 Top:TGCTGAGCAGATGACGTTTGCAAGGAGTTTTGGCC
ACTGACTGACTCCTTGCACGTCATCTGCT 
 
Bottom:CCTGAGCAGATGACGTGCAAGGAGTCAGTCAG
TGGCCAAAACTCCTTGCAAACGTCATCTGCTC 
 
MBD3 
miRNA4 
ORF 21 Top:TGCTGTTGCTTCGGAACTTCTTCCCGGTTTTGGCCA
CTGACTGACCGGGAAGATTCCGAAGCAA 
 
Bottom:CCTGTTGCTTCGGAATCTTCCCGGTCAGTCAGT
GGCCAAAACCGGGAAGAAGTTCCGAAGCAAC 
 
MBD3 
miRNA5 
ORF 95 Top:TGCTGTTAGCATCTTGCCCGTGCGGAGTTTTGGCC
ACTGACTGACTCCGCACGCAAGATGCTAA 
 
Bottom:CCTGTTAGCATCTTGCGTGCGGAGTCAGTCAGT
GGCCAAAACTCCGCACGGGCAAGATGCTAAC 
 
MBD3 
miRNA6 
ORF 107 Top:TGCTGTCACCTTGCTCATTAGCATCTGTTTTGGCCA
CTGACTGACAGATGCTAGAGCAAGGTGA 
 
Bottom:CCTGTCACCTTGCTCTAGCATCTGTCAGTCAGT
GGCCAAAACAGATGCTAATGAGCAAGGTGAC 
 
LacZ 
miRNA 
ORF 2399 Top:TGCTGAAATCGCTGATTTGTGTAGTCGTTTTGGCC
ACTGACTGACGACTACACATCAGCGATTT 
 
Bottom:CCTGAAATCGCTGATGTGTAGTCGTCAGTCAGT
GGCCAAAACGACTACACAAATCAGCGATTTC 
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Table IV. Bovine NANOG fragment that was cloned into PB-TRE-NANOG and CMV-
NANOG plasmids 
 
Full Sequence of NANOG fragment (with SalI and NotI cut sites) 
ATTGTCGACATGAGTGTGGGCCCAGCTTGTCCCCAAAGCCTGCTTGGCCCCG
AAGCATCCAACTCTAGGGAATCTTCACCCATGCCTGAAGAAAGTTACGTGTC
CTTGCAAACGTCATCTGCTGACACCCTCGACACGGACACTGTCTCTCCTCTTC
CCTCCTCCATGGATCTGCTTATTCAGGACAGTCCTGATTCTTCCACAAGCCCC
AGAGTGAAACCACTGTCCCCGTCTGTGGAGGAGAGCACAGAGAAGGAAGAG
ACGGTCCCGGTCAAGAAACAAAAGATTAGAACTGTGTTCTCGCAGACCCAGC
TGTGTGTGCTCAATGACAGATTTCAGAGGCAGAAATACCTCAGTCTCCAGCA
AATGCAAGAACTTTCCAACATCTTGAACCTCAGCTACAAGCAGGTGAAGACC
TGGTTCCAGAACCAGAGAATGAAATGTAAGAAATGGCAGAAAAACAACTGG
CCGAGGAATAGCAATGGCATGCCTCAGGGGCCAGCAATGGCAGAATACCCA
GGCTTCTATTCCTACCACCAGGGGTGTTTGGTGAACTCTCCTGGAAACCTGCC
CATGTGGGGTAACCAGACCTGGAATAACCCCACGTGGAGCAACCAGAGCTGG
AACAGTCAGTCTTGGAGCAACCACTCCTGGAACAGTCAGGCCTGGTGCCCCC
AAGCCTGGAATAACCAGCCTTGGAACAATCAGTTCAACAACTACATGGAGGA
ATTCCTGCAGCCCGGGATCCAGCTCCAGCAGAATTCTCCCGTCTGTGATCTGG
AGGCCACCCTGGGAACTGCTGGGGAAAATTATAACGTTATACAGCAAACTGT
CAAGTATTTCAATTCCCAGCAGCAAATCACTGATTTATTCCCAAACTACCCTC
TCAACATACAGCCTGAAGATTTGTAAGCGGCCGCATA 
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Appendix III. Molecular Biology Reagents and Stocks 
 
Table V. DNA and mRNA analysis reagents 
Reagent Source 
1x TAE buffer 40mM tris base, 20mM acetic acid, 
1mM EGTA in milliQ H2O 
1 Kb+ DNA LadderTM (1 µg/µl) Invitrogen (USA) 
5x DNA loading buffer 30% glycerol, 1% orange G dye in 
milliQ H2O 
5x First-Strand Buffer [250mM Tris-HCl, 375mM 
KCl, 15mM MgCl2] 
Invitrogen (USA) 
Agarose UltraPureTM Powder Invitrogen (USA) 
dATPs (10mM) Invitrogen (USA) 
dNTP mix (10mM) Invitrogen (USA) 
FastStart 10x buffer Roche (Germany) 
FastStart Taq DNA polymerase Roche (Germany) 
MgCl2 (25mM) Roche (Germany) 
Random hexamer primers (50µM) Roche (Germany) 
RNaseOUTTM Recombinant Ribonuclease Inhibitor 
(40 U/µl) 
Invitrogen (USA) 
SuperScriptTM III Reverse Transcriptase (200 U/µl) Invitrogen (USA) 
SYBR® Safe DNA Gel Stain Invitrogen (USA) 
T4 DNA ligase Invitrogen (USA) 
T4 DNA ligase buffer Invitrogen (USA) 
Takara Bio SYBR® Premix Ex TaqTM (Tli RNaseH 
Plus) 
Clontech Laboratories Inc. (USA) 
 
Table VI. Protein analysis reagents 
Reagents Source 
Blocking solution 5% goat or donkey serum in PBS 
Hoechst 33342 nuclear stain Sigma Aldrich (Switzerland) 
Quench solution 50mM NH4Cl 
PFA fixing solution, pH 7 4% depolymerised (w/v) PFA, 4% 
(w/v) sucrose,  in PBS with phenol 
red indicator 
ProLong® Diamond Antifade Mountant Life Technologies (USA) 
X-Gal staining solution, pH 7.5 20mM K3Fe(CN)6, 20mM 
K4Fe(CN)6, 2mM MgSO4, 100mM 
Na2HPO4, 0.02% NP-40, 0.01% 
deoxycholic acid in milliQ H2O 
 
Table VII. Stock reagents 
Reagent Source 
Acetic acid Thermo Fisher Scientific (USA) 
Deoxycholic acid Sigma Aldrich (Switzerland) 
Donkey Serum GIBCO, Life Technologies (USA) 
DMSO Sigma Aldrich (Switzerland) 
EDTA Invitrogen (USA) 
EGTA Sigma Aldrich (Switzerland) 
Ethanol Thermo Fisher Scientific (USA) 
Fetal Calf Serum GIBCO, Life Technologies (USA) 
Gelatin Sigma Aldrich (Switzerland) 
Goat Serum GIBCO, Life Technologies (USA) 
Glycerol J.T. Baker® chemicals (USA) 
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Isopropanol LabServ (Ireland) 
KCl Sigma Aldrich (Switzerland) 
K3Fe(CN)6 BDH Ltd. (UK) 
K4Fe(CN)6 Sigma Aldrich (Switzerland) 
KH2PO4 Sigma Aldrich (Switzerland) 
Methanol Thermo Fisher Scientific (USA) 
MgCl2 J.T. Baker® chemicals (USA) 
MgSO4 Sigma Aldrich (Switzerland) 
Nonidet® P 40 detergent Sigma Aldrich (Switzerland) 
Na2HPO4 Sigma Aldrich (Switzerland) 
NaCl J.T. Baker® chemicals (USA) 
NP-40 detergent Sigma Aldrich (Switzerland) 
Orange G dye Sigma Aldrich (Switzerland) 
Ponceau-S Sigma Aldrich (Switzerland) 
SDS Sigma Aldrich (Switzerland) 
Tris base J.T. Baker® chemicals (USA) 
Triton X-100 Sigma Aldrich (Switzerland) 
Tween Bio-Rad (USA) 
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Appendix IV. Cell Culture Information 
 
Table VIII. Bacterial cell culture reagents 
Reagent Source 
Luria-Bertani (LB) broth (25g/L) Invitrogen (USA) 
LB agar Invitrogen (USA) 
SOC medium Invitrogen (USA) 
 
Table IX. Mammalian cell lines 
Cell Line Source 
Bovine Embryonic Fibroblasts (BEFs) Andria Green, AgResearch Ruakura 
CCL44 ATCC (USA) 
EF5-TET Andria Green, AgResearch Ruakura 
EOG-TET-NANOG Andria Green, AgResearch Ruakura 
HeLa ATCC (USA) 
 
Table X. Mammalian cell culture reagents 
Reagent Details Source 
Cryoprotectant Solution FCS + 20% DMSO Homemade 
DMEM/F12 + GlutaMAX 2.438g/L Sodium bicarbonate, 
sodium pyruvate 
GIBCO, Life 
Technologies (USA) 
Doxycycline Hyclate 2 mg/ml stock Sigma Aldrich 
(Switzerland) 
Opti-MEM 2.4g/L Sodium bicarbonate, L-
Glutamine 
GIBCO, Life 
Technologies (USA) 
10x PBS 80g NaCl, 2g KCl, 14.4g Na2HPO4, 
2.4g KH2PO4 in 1L milliQ H2O 
Homemade 
TrypLETM Express Used for lifting off fibroblast cells GIBCO, Life 
Technologies (USA) 
Trypsin-EDTA (0.25%), 
phenol red 
Used for lifting off epithelial cells GIBCO, Life 
Technologies (USA) 
 
Table XI. Cell seeding density and media volume for various size tissue culture dishes 
Tissue Culture Dish Area (cm2) Seeding density Volume of media 
96-well 0.3 0.1 x 105 200 µl 
48-well 0.7 0.3 x 105 400 µl 
4-well/24-well 2 0.5 x 105 500 µl 
12-well 4 1 x 105 1 ml 
3cm/6-well 9.6 2 x 105 2 ml 
6cm 28 5 x 105 5 ml 
10cm 78.5 1 x 106 10 ml 
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Appendix V. Commercial Kits, Software, and Equipment 
 
Table XII. Commercial kits 
Kit Source 
BLOCK-iTTM Pol II miR RNAi Expression Vector 
Kit 
Invitrogen (USA) 
Lipofectamine® LTX with PLUSTM reagent Invitrogen (USA) 
NeonTM Transfection System Invitrogen (USA) 
PureLink® HiPure Plasmid Filter Maxiprep Kit Invitrogen (USA) 
PureLink® HiPure Plasmid Filter Miniprep Kit Invitrogen (USA) 
RNAGem Tissue ZyGEM (NZ) 
TOPO-TA Cloning® Kit Invitrogen (USA) 
Wizard® SV Gel & PCR Clean-Up System Promega (USA) 
 
Table XIII. Software 
Software Source 
BLAST NCBI (USA) 
BLOCK-iTTM RNAi Designer Invitrogen (USA) 
Chromas Lite Technekysium pty ltd (Australia) 
Geneious Biomatter Ltd (NZ) 
ImageJ NIH (USA) 
LightCycler® Roche (Germany) 
Microsoft Excel 2010 Microsoft (USA) 
Quantity One BioRad (USA) 
Spot Basic Spot Imaging Solutions (USA) 
 
Table XIV. Equipment 
Equipment Manufacturer 
Biofuge fresco centrifuge Heraeus (Germany) 
Biofuge primo centrifuge Heraeus (Germany) 
Clean bench fume hood Pall Corporation (USA) 
Dual-intensity transilluminator UVP (USA) 
Eppendorf centrifuge 5417C Eppendorf (Germany) 
Eppendorf Mastercycler gradient PCR machine Eppendorf (Germany) 
EVOS fluorescence microscope AMG (USA) 
Gel Doc 2000 Bio-Rad (USA) 
Infors HT ecotron incubator (Bacterial culture) Infors HT (Switzerland) 
LC carousel centrifuge 2.0 Roche (Germany) 
Leica DFC290 light microscope Leica (Germany) 
LightCycler 2.0 Roche (Germany) 
Minispin plus centrifuge Eppendorf (Germany) 
Nanodrop ND-1000 Thermo Scientific (USA) 
NeonTM transfection system Invitrogen (USA) 
Nikon TMS light microscope Nikon (Japan) 
Olympus BX50 fluorescent microscope Olympus (Japan) 
Sanyo incubator (Transformation plates) Sanyo (Japan) 
Sorvall RC5C Plus centrifuge Thermo Scientific (USA) 
Spot RT3 camera Spot Imaging Solutions (USA) 
Sub-cell gel tank Bio-Rad (USA) 
Thermo Forma series II water jacketed CO2 
incubator 
Thermo Scientific (USA) 
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